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ABSTRACT
While enantiomers, i.e., mirror-image-like stereoisomers, contain the same 
atoms and functional groups, differences in the three-dimensional arrangement of 
those atoms or groups may result in different biological activities. Regulatory 
agencies such as the US Food and Drug Administration require quantitative detection 
and characterization of individual enantiomers of chiral drugs and their metabolites 
because the pharmacodynamic, pharmacokinetic, and toxicological properties of 
enantiomers may differ. Therefore, separation and detection of enantiomers are 
crucial to the understanding of their biological roles. Antibodies raised against chiral 
haptens have the potential of discriminating between enantiomers, which makes them 
one of only a few tailor-made types of chiral selectors. In this dissertation, antibodies 
were raised against D- and L-a-hydroxy acids, respectively. Both polyclonal 
antibodies from rabbits and monoclonal antibodies from murine hybridomas were 
produced that stereoselectively bind to a wide range of a-hydroxy acids, including 
both aromatic and aliphatic a-hydroxy acids. No detectable interaction was seen with 
the “opposite” enantiomer. Further studies confirmed that the hydroxyl/carboxyl/ 
hydrogen triad about the stereogenic center is essential for antibody binding as no 
interaction was observed with structurally closely related compounds such as a-amino 
acids. Conversely, previously produced stereoselective anti-a-amino acid antibodies
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bound only to a-amino acids of the correct configuration and not to a-hydroxy acids. 
The remarkable stereoselectivity and class specificity of these antibodies enabled the 
development of fluorescence-based immunoassays for the simultaneous detection of 
D-phenylalanine, L-phenylalanine, D-phenyllactic acid, and L-phenyllactic acid using 
four antibodies, each of which was labeled with a unique fluorophore. Furthermore, 
the utility of an anti-a-hydroxy acid antibody for enantiomer separation in chiral 
immunoaffinity chromatography was demonstrated.
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CHAPTER I
INTRODUCTION
Stereoisomers are molecules that have the same constituents and structural 
formula but differ in the spatial arrangement of certain atoms or groups of atoms. 
Enantiomers are stereoisomers that are nonsuperimposable mirror images and rotate 
plane-polarized light equally in opposite directions. Separation and detection of 
enantiomers remains challenging since they share most of their chemical and physical 
properties, such as melting point, boiling point, and solubility.
Louis Pasteur, in 1848, first discovered enantiomers when he found that 
tartaric acid formed distinct crystals, which are comprised of its pure enantiomeric 
forms.1 Ten years later, Pasteur also recognized that in a biological system, the 
metabolization of each enantiomer might be different.2 A better understanding of the 
physiological basis of chiral discrimination in biological systems resulted from the 
work of Emil Fischer and contemporaries, who showed that proteins are able to 
distinguish between enantiomers.3'6 Numerous examples of differences in the 
biological activity of enantiomers have been described. For example, Piutti 
discovered as early as in the 1880s that L-asparagine is tasteless while D-asparagine 
tastes sweet.7 Enantiomers may also have a distinct odor. (i?)-limonene has an odor 
of oranges while (5)-limonene has an odor of lemons. Although (/?)-limonene is
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extracted from oranges and (S)-limonene from lemons, their differences in odor had 
been attributed to impurities until Friedman and Miller synthesized the enantiomers of 
limonene in 1971.8
The enantiomers of drugs may also differ in their biological activities; one 
enantiomer may have a desired effect while the other may be toxic. For example, D- 
penicillamine is used to treat both heavy metal poisoning and Wilson’s disease, which 
is a hereditary defect in copper metabolism;9 it is also used to treat arthritis.10 L- 
penicillamine, however, is toxic.10 In other cases, the two enantiomers of a drug are 
used to treat different diseases. For example, (5)-thyroxine is used to treat thyroid 
deficiency while (7?)-thyroxine decreases serum cholesterol.11
Since enantiomers of a drug can have such drastic differences in activity, the 
US Food and Drug Administration (FDA) issued a policy statement in 1992 requiring 
pharmacodynamic, pharmacokinetic, and toxicological studies of individual 
enantiomers of drugs.12 Therefore, suitable techniques for the detection and separation 
of enantiomers are needed to evaluate the enantiomeric composition of synthetic
1Tproducts and to determine the stereochemistry of drugs and metabolites.
A variety of methods have been developed for the detection and separation of 
enantiomers. The oldest method of enantiomer resolution is crystallization. While 
some enantiomers, like tartaric acid, can be purified directly by crystallization, others 
are first reacted with an optically pure compound to form diastereomers so as to aid in 
the formation of pure crystals.14
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One of the most popular methods for both detection and separation of 
enantiomers remains chiral chromatography, which is more versatile and faster than 
crystallization. The two variants of chiral chromatography are known as the direct and 
indirect methods. In the indirect method, enantiomers are reacted with another 
enantiomerically pure compound, a chiral derivatizing agent, to form diastereomers, 
which can be resolved on standard “achiral” chromatographic supports due to 
differences in their chemical and physical properties.15 Despite the fact that this 
method is used for both analytical- and preparative-scale enantioseparations, 
numerous limitations remain.15 Appropriate functional groups must be available on 
the chiral target molecule. The chiral derivatizing agent should be cheap, readily 
available, and optically pure. The derivatization reaction should be quantitative, and 
available chromatographic columns should be able to separate the resulting 
diastereomer. In the case of preparative-scale separations, the diastereomer must be 
cleaved to yield the desired, optically pure product and the chiral derivatizing agent in 
high yields. Additionally, the reaction conditions for both derivatization and cleavage 
must be mild enough to prevent racemization of either the chiral derivatizing agent or 
the target molecule. Indirect separations are generally multistep and time-consuming 
processes.
In direct chromatographic methods, separations can be performed without 
chemical modification of the chiral target molecules. Instead, enantioseparations are 
achieved via the formation of transient pseudo-diastereomeric complexes between a 
so-called chiral selector and the individual enantiomers of a chiral compound.
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Chromatographic separations exploit the difference in the free energies of the 
transient complexes of the two enantiomers.16 The chiral selector can be immobilized 
to solid-phase support materials, thus producing a so-called chiral stationary phase 
(CSP); separations can be performed with an achiral mobile phase. Alternatively, the 
chiral selector can be used as a chiral mobile phase additive with an achiral stationary 
phase. In both approaches, the chiral selector and the enantiomer interact via a 
combination of noncovalent forces including hydrogen bonding between acidic and 
basic sites, electrostatic interactions between polar/charged sites, n-n interactions of 
aromatic groups, and van der Waals attraction between hydrophobic portions of the 
interacting chiral selector and the enantiomer. Because enantiomers differ in their 
three-dimensional structure, steric interactions may also play an important role in 
recognition by chiral selectors. A wide variety of chiral selectors are commercially 
available such as macrocyclic antibiotics, jr-donor/71-acceptor systems, oligo- and 
polysaccharides, synthetic polymers, ligand-exchange selectors, crown ethers, and 
proteins like bovine serum albumin (BSA).17 Many of these chiral selectors have also 
been used for enantiomer separations in capillary electrophoresis and capillary 
electrochromatography.18’19 Other chiral discrimination methods that are used to 
detect the interaction between enantiomers and a chiral selector are based on
techniques like nuclear magnetic resonance (NMR),20 mass spectrometry,21 or
• 22 • •microarrays. Because typical chiral selectors are not designed for a specific
enantiomer, the interaction between the enantiomer and chiral selector must be 
determined experimentally or predicted using a model derived from experimental
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results. The enantioselectivity of a given chiral selector, however, can only be 
usefully predicted for molecules closely related to the enantiomers used in the original 
experiments. Additionally, data obtained from such models is generally only 
qualitative in nature.23 24
In order to avoid the often time-consuming and expensive process of 
identifying an effective chiral selector by trial and error, three methods are currently 
being investigated to produce tailor-made chiral selectors with a predetermined 
specificity: molecularly imprinted polymers (MIPs),25-27 DNA and RNA aptamers,28-34 
and antibodies.35 MIPs have been used as chiral stationary phases in high- 
performance liquid chromatography (HPLC), capillary electrophoresis, capillary 
electrochromatography, sensors, and immunoassays.36-38 MIPs, however, have 
heterogeneous binding sites with varying affinities, which typically leads to significant
-JQ
peak broadening and tailing. This effect may be increased by slow mass transfer 
kinetics due to poorly accessible binding sites and irregular particles. Poorly 
accessible binding sites are typically a result of small pore sizes, whereas the most 
common preparation method for MIPs, bulk polymerization, leads to irregularly sized 
and shaped particles.39 Irregular particles also contribute to high back pressures.39 
Furthermore, MIPs may show nonspecific interactions, especially in aqueous phases.40
More recently, DNA and RNA aptamers have been used for chiral separations 
in chromatography and capillary electrophoresis 28-34 While stereoselective aptamers 
of both DNA and RNA were produced previously,41-44 Peyrin et al. were the first to 
report the utility of stereoselective aptamers as CSP.28 Aptamers are advantageous
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because they can be synthesized chemically in a short time with high purity and 
because their binding selectivity can be manipulated by changing their sequence.45 
However, the systematic evolution of ligands by exponential enrichment procedures 
used to select for aptamers with desired binding properties can be expensive and time- 
consuming.29 Column stability must still be improved to compete with standard 
chromatographic techniques. While one of the DNA aptamers used in HPLC lasted 
for at least five months,28 another showed drastic deterioration after only two 
months.29 Chromatographic conditions have typically been limited to the use of 
aqueous solvents, although with one RNA aptamer CSP, an organic modifier was 
added to the mobile phase.30 Columns suffer from broad peaks and low efficiency due 
to slow kinetics.28 Additionally, the high specificity of aptamers has usually limited
• • • • • • « T9separation applicability to a single pair of enantiomers.
The third type of tailor-made chiral selectors are antibodies. These 
glycoproteins are produced by the humoral immune response of vertebrates.46 
Immunoglobulin G (IgG), specifically, is the class of antibodies most readily available 
from serum.47 IgGs are comprised of two identical “heavy” and two identical “light” 
chains connected by noncovalent interactions and disulfide bridges, thus forming a 
“dimer of dimers.” IgG antibodies possess two binding sites, which are formed from 
the so-called complementarity determining regions (CDRs) at the N-termini of each 
heavy and light chain pair.49 Since the sequences of the CDRs, and thus binding 
specificities, vary widely among antibodies, an animal is able to recognize millions of 
structurally different antigens. Because of this variability, the regions of the antibody
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that contain CDRs are known as “variable domains.”49 Unlike the N-terminal 
variable regions of the heavy and light chains, the sequence and structure of the 
constant domains of an antibody are largely conserved.50
In principle, antibodies can be raised against any molecule; however, 
molecules smaller than 5,000 Da are typically not immunogenic. In the early 1900s, 
though, Karl Landsteiner realized that small molecules, known as haptens, can be 
conjugated to a carrier in order to elicit an immune response.51 Because of their 
immunogenicity, proteins are most frequently used as carriers. The chemistry 
employed to couple the hapten to a carrier should result in an optimal, directed 
presentation of the target structure of the hapten on the carrier.51 The carrier-hapten 
conjugate can then be used to immunize animals and, thus, produce the desired
• * 5 1  52 •antibodies. ’ After immunization, many different B-cells are stimulated and secrete 
a wide variety of antibodies (i.e., polyclonal antibodies). Polyclonal antibodies can 
easily be obtained from the sera or interstitial fluid of mammals, such as rabbits; 
therefore, their production is cost-effective and efficient. However, because 
polyclonal antibodies comprise a heterogeneous population of immunoglobulins, there 
will be antibodies against unrelated antigens as well as antibodies with differing 
affinities for the same antigen and antibodies of different subclasses and consequently 
different biological properties. Additionally, their production is highly dependent on 
the survival of the animal. Monoclonal antibodies can be used to overcome the 
limitations of polyclonal antibodies.
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In 1975, the production of monoclonal antibodies was first pioneered by 
Milstein and Kohler, who fused myeloma cells with antibody-secreting B-cells in 
vitro, making immortalized monoclonal antibody-secreting cells, called 
hybridomas.53-56 Because each hybridoma cell line secretes a unique antibody, 
monoclonal antibodies have the same specificity and affinity for an antigen. A 
population of such antibodies, therefore, has homogeneous binding properties. The 
myeloma cells commonly used for hybridoma production lack the gene for one of two 
enzymes: either hypoxanthine-guanine-phosphoribosyl transferase (HGPRT) or 
thymidine kinase (Tk). The myeloma cells, therefore, are unable to synthesize the 
nucleotides adenosine monophosphate and guanosine monophosphate (in the case of 
HGPRT-deficient cells) or thymidine monophosphate (in the case of Tk-deficient 
cells) via the salvage pathway. Instead, the myeloma cells rely on the de novo 
•pathway for nucleotide synthesis. After fusion, the cells are cultivated in HAT 
medium, which contains hypoxanthine, aminopterin, and thymidine, to select for 
hybridoma cells. Unfused B-cells die after a few days since they are not immortal. 
Furthermore, the dihydrofolate analog, aminopterin, blocks the de novo pathway, 
which effectively kills unfused myeloma cells. The hybridoma cells, however, are 
able to synthesize nucleotides via the salvage pathway using the hypoxanthine and 
thymidine supplied in the media because the B-cells “contributed” their functional 
HGPRT and Tk genes. Because hybridoma cell lines contain the genes from the 
myeloma cells, these hybridoma cell lines are immortal. In theory, hybridoma cells 
can be cultured indefinitely or frozen for later use.
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Typically, hybridoma cells qje initially cultured in 96-well sterile microtiter 
plates following limiting dilution. In limiting dilution, the concentration of cells 
plated out should be low to increase the probability of monoclonality, yet sufficiently 
high to promote cell growth. Positive clones are selected by screening the cell-culture 
supernatant for antibodies with the desired binding characteristics. Assays commonly 
used for screening include enzyme-linked immunosorbent assay (ELISA), 
radioimmunoassay (RIA), immunofluorescence, cytotoxicity assays, and 
immunoprecipitation. Positive clones are subcloned by multiple rounds of limiting 
dilution to ensure monoclonality until virtually every well tested is positive. The 
hybridomas that secrete the antigen-specific antibody can then be cultured in bigger 
cell culture flasks and may be used to up-scale production either in bioreactors or 
through ascites production in the peritoneal cavity of mice.
Both polyclonal and monoclonal antibodies have become increasingly 
important tools in analytical biochemistry for “achiral applications.”57 However, even 
though Landsteiner, in 1928, demonstrated that antibodies may discriminate between 
stereoisomers, including enantiomers,58 antibody stereoselectivity has found only 
limited use for “chiral” applications in, e.g., chromatography, extraction, 
immunoblotting, immunohistochemistry, immunoassays, and sensors.35 In order to 
establish antibodies as chiral selectors for routine use, highly stereoselective and 
specific antibodies need to be produced against a wider range of chiral compounds. In 
addition, the utility of these antibodies in a variety of analytical techniques should be 
demonstrated.
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The widest variety of applications using stereoselective antibodies have been 
developed by Hofstetter and Hofstetter.35 They produced poly- and monoclonal 
antibodies against protein conjugates of p-amino-D- and -L-phenylalanine (Phe), 
respectively. These antibodies recognize not only the haptens but also other a-amino 
acids (AAs) of the correct configuration. That is, the anti-D-AA antibodies bind to D- 
AAs, whereas the anti-L-AA antibodies bind to L-AAs.59,60 While the antibodies 
primarily recognize the amino/carboxyl/hydrogen triad about the a-carbon, the nature 
of the side chain is of less importance but affects the overall binding affinity. AAs 
most similar in structure to the hapten show the strongest binding to the antibodies. 
Therefore, aromatic AAs generally are bound more strongly than aliphatic AAs. 
However, AAs lacking the amino/carboxy 1/hydrogen triad such as (3-alanine or proline 
show no binding interaction with the antibody as determined by competitive 
ELISAs.59 The anti-AA antibodies have been used for chiral discrimination of AAs in 
various bioanalytical techniques such as immunoassays, chromatography, and 
sensors.35,59'71
A primary objective of this dissertation was to produce stereoselective 
antibodies against the structurally related class of compounds, the a-hydroxy acids 
(AHAs). AHAs represent one of the most important classes of biologically relevant 
chiral molecules since they are involved in various biological processes.72,73 They are 
abundant in nature and have been extracted from animal tissues, plants, and 
microorganisms.74 Determination of the stereochemistry of AHAs is essential for 
understanding their exact roles in biochemical processes and to diagnose and monitor
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certain diseases.75 Metabolic acidosis, for example, results from an accumulation of 
organic acids in the blood.
One variant of metabolic acidosis, lactic acidemia, is caused by the abnormal 
accumulation of lactic acid in the blood.76 The stereospecific detection of lactic acid 
enantiomers can be used to determine the nature and origin of the disease.75 L-Lactic 
acidosis can be caused by, e.g., hypotension or as a side effect of drugs such as 
nucleoside reverse-transcriptase inhibitors.77,78 Because nucleoside reverse- 
transcriptase inhibitors inhibit mitochondrial DNA polymerase y, mitochondrial DNA 
cannot be properly replicated. The body, therefore, is forced to rely on anaerobic 
metabolism instead of oxidative phosphorylation, which in turn leads to the 
accumulation of lactic acid. 77,78 D-Lactic acidosis can be caused by short bowel 
syndrome and the overpopulation of bacteria such as Lactobacillus in the colon.76
Another variant of metabolic acidosis, maple syrup urine disease (MSUD), is 
caused by a deficiency of the branched-chain a-keto acid dehydrogenase complex. 
This deficiency results in the accumulation of branched-chain AAs as well as the 
corresponding a-keto acids and AHAs. It has been known that MSUD can result in 
neurological damages and mental retardation. The elucidation of the enantiomeric 
ratios of the relevant metabolites can be used to determine metabolic enzyme activities 
involved in MSUD.79
AHAs are also contained in a wide array of cosmetics such as creams and
lotions. While these AHAs are intended to reduce wrinkles, spots, and other signs of
• 80 aging and sun damage, they also make users more sensitive to sunlight—specifically
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ultraviolet light.81 This, in turn, increases the risk of skin cancer. AHAs, therefore,
Q-y | ,
are under increasing scrutiny by the FDA. In fact, many scientists are advocating
83reclassification of AHAs as drugs by the FDA.
In synthetic organic chemistry, enantiomerically pure AHAs are both 
important products and chiral building blocks.84,85 For example, optically active ether- 
linked p-lactams have been synthesized via 4-bromo-2-hydroxybutanoic acid esters
oz
derived from (R)- or (S)-malic acid. The ester forms of AHAs can also be used in
reactions such as metal-catalyzed aldol and Michael reactions to synthesize bi- and
tridentate phosphane and thioether ligands, thiodiglycols, and diglycols.87,88 Many
natural products have been synthesized from AHAs. For example, the phosphatase
inhibitor motuporin, originally isolated from the marine sponge Theonella swinhoei,
80can be synthesized from D-mandelic acid. Eremantholide A from Ermanthus 
elaeagnus can also be synthesized from D-lactic acid. This compound has been 
investigated in vitro as an antitumor agent in a range of cell lines.90 Other examples of 
natural products include integerrimine and monocrotaline, which were previously 
isolated from a variety of plants, including the families Boraginaceae (all genera), 
Compositae (genera Senecioneae and Eupatorieae), and Leguminosae (genus 
Crotalaria). Both integerrimine and monocrotaline can be synthesized from (i?)-malic 
acid.91,92
Because of their biodegradability and biocompatibility, poly-AHAs have 
recently become popular in biomedical and pharmaceutical applications.93 Polylactic 
acid, polyhydroxybutyric acid, and polyglycolic acid have all been utilized as
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polymeric drug carriers94 and bioresorbable sutures.95,96 Degradation of these 
biopolymers in living organisms, e.g., humans, occurs by either enzymatic or 
nonenzymatic hydrolysis resulting in both water-soluble and water-insoluble 
oligomers. Water-soluble oligomers are readily excreted, whereas water-insoluble 
oligomers are processed by macrophages.97 Depending on the particular use of these 
poly-AHAs, the hydrolysis rates can be controlled by choosing suitable enantiomeric 
ratios. This is based on the fact that poly-L-lactic acid degrades more rapidly than 
poly-D-lactic acid. However, both poly-D- and poly-L-lactic acids are highly 
crystalline and, therefore, degrade more slowly than poly-D,L-lactic acid.98 
Additionally, functional groups can be included in the polymer to increase the 
hydrophilic nature, thus increasing degradation rates.99,100
Because chiral AHAs are used in such a wide variety of applications ranging 
from cosmetics to organic synthesis and biopolymers, their preparation is of 
considerable technological and commercial interest. Both enzymatic and 
nonenzymatic methods for the enantioselective synthesis of AHAs have been 
developed. One example of enzymatic synthesis is the oxidation of racemic 1,2-diols 
to enantiomerically pure L-a-hydroxy aldehydes by horse liver alcohol 
dehydrogenase, followed by conversion to L-AHAs catalyzed by aldehyde 
dehydrogenase.101 Other examples include the reduction of carbonyl compounds by 
NADH-dependent oxido-reductases like lactic acid dehydrogenase (LDH).102 LDH 
catalyzes the stereospecific reduction of pyruvate to either D- or L-lactate depending 
on the specificity of the enzyme used. Thus, LDH from a variety of sources such as
R ep ro d u ced  with p erm issio n  o f  th e  copyrigh t ow n er. Further reproduction  prohibited w ithout p erm ission .
14
103rabbit muscle, bovine heart, and lobster tail can be used to synthesize L-lactate. 
Alternatively, LDH from Leuconostoc mesenteroides produces D-lactate.104 Other 
enzymatic methods are used to synthesize structurally related compounds, which, in 
turn, can be converted to enantiomerically pure AHAs. Baker’s yeast (Saccharomyces 
cerevisiae) has been used to convert a-keto esters to enantiopure a-hydroxy esters, 
which can easily be hydrolyzed to yield pure AHAs.105 Nitrilases can be used to 
stereospecifically add a nitrile to aldehydes in order to produce a-hydroxy 
cyanohydrins. The cyanohydrins are then converted to chiral AHAs with retention of 
the stereochemistry by acid hydrolysis.106
Nonenzymatically, AHAs are synthesized via various asymmetric synthesis 
methods such as the reduction of a-keto acid-derived hemiacetals107 or a-oxo 
esters,108 asymmetric oxygenation of chiral imide enolates,109 oxidation of terminal
alkenes,110 and asymmetric hydrogenation of both enol esters111 and a-functionalized
112ketones. Alternatively, chiral AHAs can be synthesized from the corresponding
1 IT
AAs by diazotization followed by acid hydrolysis.
Despite the progress made in the asymmetric synthesis of AHAs, chiral 
discrimination remains important for testing the purity of not only synthesized AHAs 
but also those isolated from biological samples. Commonly, AHAs are separated into 
their enantiomers by chromatographic and electrophoretic systems using some of the 
same chiral selectors that are used to separate AAs; these include ligand-exchange 
selectors,114 macrocyclic antibiotics,115 Ti-donor/71-acceptor systems,116 and proteins.117
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Interestingly, crown ethers can only be used for AA separations and not for the
118separation of AHAs.
Determination of lactic acid enantiomers is also carried out enzymatically 
using D- or L-lactic acid dehydrogenase, which converts either D- or L-lactic acid to 
pyruvate. Since lactic acid dehydrogenase is NADH dependent, the concentration of 
produced D- or L-lactic acid can be correlated to the concentration of NADH measured 
at 340 nm.119 In 1998, McKendry et al. developed a chemical force microscopy
• 1 ”70 • •method for the chiral discrimination of mandelic acid. D- or L-Mandelic acid was 
immobilized on a gold surface while a Pirkle-type chiral selector was immobilized on 
an atomic force microscopy tip. Interaction between the immobilized chiral selector 
and the mandelic acid enantiomers on the gold surface resulted in measurable 
differences in adhesion and friction forces, which were then used to distinguish
1 ”70between the two enantiomers.
The first objective of this dissertation was to produce both polyclonal and 
monoclonal antibodies that stereoselectively bind to the enantiomers of AHAs. In 
order to produce such antibodies, conjugates of p-amino-D- and p-amino-L- 
phenyllactic acid (PLA), respectively, and keyhole limpet hemocyanin (KLH) had to 
be synthesized and used to immunize rabbits and mice following the method 
developed by Hofstetter et al. for the production of anti-AA antibodies.59
The second objective of this work was to characterize the binding specificity 
and stereoselectivity of the produced antibodies using both noncompetitive and 
competitive ELISAs. The affinity of these antibodies to a variety of different AHAs
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was to be tested in order to evaluate the influence of the nature of the side chain on 
the overall affinity.
Because AHAs and AAs are structurally very similar classes of compounds 
that differ only in one functional group linked to the stereogenic center, a further goal 
of this dissertation was to test these antibodies for their ability to distinguish between 
different classes of compounds. Additional ELISAs had to be performed to test the 
binding of anti-AHA antibodies to AAs and, conversely, the binding of previously 
produced anti-AA antibodies to AHAs. The anti-AHA antibodies were also to be 
tested for their ability to bind to other structurally related compounds in order to 
further evaluate their specificity.
The final objective of this dissertation was to demonstrate the utility of these 
antibodies in analytical applications such as chiral chromatography and 
immunoassays.
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MATERIALS AND METHODS 
Chemicals
D- and L-PLA, 2-hydroxyisocaproic acid, and L-Phe were purchased from 
Aldrich (Milwaukee, WI). The following chemicals were from Sigma (St. Louis, 
MO): 2-hydroxydecanoic acid, 2-hydroxyoctanoic acid, D-mandelic acid, D-Phe, and 
tyramine. D- and L-a-hydroxyisovaleric acid, L-lactic acid sodium salt, and L- 
mandelic acid were purchased from Fluka (Milwaukee, WI). All these compounds 
were of the highest purity available.
Complete Freund’s adjuvant (CFA), incomplete Freund’s adjuvant (IFA), 
bovine serum albumin (BSA), gelatin, and keyhole limpet hemocyanin (KLH) were 
from Sigma (St. Louis, MO). All horseradish peroxidase-conjugated goat anti-rabbit, 
goat anti-mouse, and donkey anti-goat secondary antibodies were purchased from 
Jackson Immuno Research Laboratories, Inc. (West Grove, PA). The mouse 
monoclonal antibody isotyping reagents were from Sigma (St. Louis, MO). Goat anti­
mouse IgG DyLight™ 647-conjugated antibody, goat anti-rabbit DyLight™ 
547-conjugated antibody, DyLight™ 547 NHS Ester, DyLight™ 647 NHS Ester, 
DyLight™ 800 NHS Ester, and DyLight™ 490 NHS Ester were from ThermoFisher
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(formerly Pierce Biotechnology, Rockford, IL). All anti-AA antibodies used in this 
study were previously produced by Drs. Oliver and Heike Hofstetter.59,60
The following cell culture reagents were purchased through Sigma (St. Louis, 
MO): RPMI-1640 medium, HAT media supplement (50x), sodium pyruvate, sodium 
hydroxide, hydrochloric acid, D-glucose, sodium bicarbonate, HEPES, horse serum 
donor herd heat inactivated (HS), benzalkonium chloride, dimethyl sulphoxide, and 
polyethylene glycol (PEG, MW 1,300-1,600). Antibiotic-antimycotic was from 
Invitrogen (Grand Island, NY).
1,2-Phenylenediamine (OPD) was from Aldrich (Milwaukee, WI). N,N’- 
disuccinymidyl carbonate (DSC) and 4-dimethylaminopyridine (DMAP) both were 
from NovaBiochem (La Jolla, CA). N, N  -dimethylformamide (DMF) was from 
Sigma-Aldrich (Milwaukee, WI).
Other salts were purchased from Fisher Scientific (Fair Lawn, NJ) and were of 
analytical grade. Preparation of buffers and cell culture media is described in the 
Appendix. Organic solvents were from Aldrich (Milwaukee, WI) and were all of 
reagent grade. All water was deionized using a Milli-Q water purification system 
from Millipore (Bedford, MA); ultrapure water for cell culture use came from the 
Core DNA Analysis Lab of NIU’s Department of Biological Sciences.
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Ninety-six-well MaxiSorp polystyrene microtiter plates were from Nunc 
(Rochester, NY); 96-well Immulon Immunoassay microplates were from Dynex 
Technologies (Chantilly, VA). A comparison of the two types of plates showed no 
significant difference in ELISA results. Nucleosil silica (100-3) was obtained through 
Alltech Associates, Inc. (Deerfield, IL). PEEK tubing (0.75 mm), a 2 pm frit-in-a- 
ferrule and a high-pressure-adjustable-back pressure regulator set to 43 bars were from 
Upchurch Scientific (Oak Harbor, WA). Sepharose CL4B was purchased from 
Pharmacia (Uppsala, Sweden). Centriplus centrifugal filter devices with molecular 
weight cut-offs of 30 and 100 kDa, respectively, were from Millipore (Bedford, MA). 
The Melon™ Gel IgG purification kit, 4-20% Precise™ protein gels (12-well), 
BupH™ Tris-HEPES-SDS running buffer, GelCode® blue stain reagent, and 
Reacti-Bind™ White Opaque 96-well plates were from ThermoFisher (formerly 
Pierce Biotechnology, Rockford, IL).
Twelve-week-old female New Zealand white rabbits and eight-week-old 
female BALB/c mice were both purchased from Harlan (Indianapolis, IN). The 
P3x63AG8 myeloma cell line was from ATCC (Manassas, VA).
Twelve- and 24-well tissue culture plates and 25, 250, and 600 mL tissue 
culture flasks were from Falcon (Franklin Lakes, NJ); 96-well cell culture plates and
‘j
25 cm cell culture flasks were from Coming, Inc. (Coming, NY). Petri dishes as well 
as both 2 and 10 mL serological pipets were from Fisher Scientific (Fair Lawn, NJ).
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A Nalgene™ cryo 1°C freezing container was purchased from Nalgene (Rochester, 
NY).
Instruments
The purifier class II biosafety cabinet model 3620904A was from Labconco 
(Kansas City, MO) and was installed and certified by Air Contamination Technologies 
(Chicago, IL). The inverted microscope Nikon ECLIPSE TS 100 for cell culture use 
was from Fryer Company, Inc., Scientific Instruments (Huntley, IL). The lab line CO2 
incubator model 460 was purchased from Fisher Scientific (Fair Lawn, NJ). The 
Locator 4 cryo biological storage system was from Thermolyne (Dubuque, Iowa).
The GS-6R and Model J2-21 centrifuges came from Beckman Coulter (Fullerton,
CA); the lyophilizer model line FreeZone 4.5 and rotary evaporator were both from 
Labconco (Kansas City, MO). The 200 MHz nuclear magnetic resonance (NMR) 
instrument was from Bruker Biospin Corp. (Billerica, MA). The FT-IR Genesis 
spectrophotometer was from Mattson (Madison, WI). The AT AGO polarimeter 
model AP-300 used for determination of optical rotations was from National 
Microscope Exchange (Carnation, WA). The Esquire 3000 ion trap mass spectrometer 
(MS) was fitted with an electrospray source and came from Bruker Daltonics, Inc. 
(Billerica, MA). The 1000/500 model power supply for gel electrophoresis was from 
BioRad (Hercules, CA). The RP-1 model peristaltic pump was purchased from Rainin 
(Emeryville, CA). The plate reader with FLOUstar 403 Galaxy control and evaluation
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software came from BMG Labtechnologies (Offenburg, Germany). Alltech Slurry 
Packer model 1666 fitted with a 20 mL reservoir was from Alltech (Deerfield, IL).
The chromatography system was from Hitachi (Naperville, IL) and consisted of an L- 
7400 UV detector fitted with a semi-micro flow cell, an L-7100 pump, a degasser, and 
a D-7000 interface. System Manager V 4.0 software was used for both instrument 
control and data collection. The Rheodyne 7725i injector, also from Hitachi 
(Naperville, IL), was fitted with a 5 pL injection loop.
Synthesis of Immunogens 
p-Nitro-P- and -L-Phenyllactic Acid
/7-Nitro-D- and -L-PLA were each synthesized separately from D- and L-PLA 
as follows (Figure 1): 500 mg of D- or L-PLA were mixed with three parts of 
concentrated sulfuric acid at room temperature. The solutions were then cooled on 
ice. One part of concentrated nitric acid was added dropwise to the cooled solutions 
while stirring. After ten minutes, 10 mL of cold water were added to the reaction 
mixtures; 3M ammonium hydroxide was used to adjust the pH to 9. The product, 
p-nitro-D- or -L-PLA, were first lyophilized, then recrystallized from methanol, and 
finally purified by thin-layer chromatography (TLC) using 1-butanol:waterracetic acid 
(4:1:1) as solvent.
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Figure 1: Nitration of D- or L-phenyllactic acid.
g-Amino-P- and -L-Phenyllactic Acid
p-Nitro-D- and -L-PLA were hydrogenated to p-amino-D- and -L-PLA, 
respectively (Figure 2). Four hundred mg of/?-nitro-D- and -L-PLA were each 
dissolved separately in methanol, and 40 mg of palladium-charcoal hydrogen catalyst 
was added to the reaction mixtures. A hydrogen-filled balloon was connected to each 
of the reaction vessels. /i-Nitro-D- and -L-PLA were hydrogenated at atmospheric 
pressure for two days under continuous stirring. The products were lyophilized, 
recrystallized from methanol, and purified by TLC using 1-butanol:water:acetic acid 
(4:1:1) as solvent.
I
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Figure 2: Hydrogenation of p-nitro-D- or -L-phenyllactic acid.
p-Azo-P- and -L-Phenvllactic Acid-Tyramine Conjugates
p-Azo-D- and -L-PLA-tyramine, respectively, were synthesized by modifying
171the method of Tabachnick and Sobotka (Figure 3). p-amino-D- and -L-PLA (15 mg 
each) were dissolved separately in 1 mL of 0.1 M hydrochloric acid and cooled on ice. 
An equimolar amount of sodium nitrite was added to the solutions of p-amino-D- and - 
L-PLA while stirring continuously. Aliquots of tyramine (60 mg each) were dissolved 
in 100 mM borate buffer, pH 8.5, and added to each of the p-amino-PLA solutions. 
The pH was adjusted to 8.5 with 0.1 M sodium hydroxide. The mixture was allowed 
to react overnight at room temperature. The resulting p-azo-D- and -L-PLA-tyramine 
conjugates were first lyophilized, then recrystallized from methanol, and then purified 
by TLC using 1-butanol:water:acetic acid (4:1:1) as solvent.
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Figure 3: Diazotization reaction resulting in the formation of p-azo-D- and -L- 
phenyllactic acid tyramine conjugates.
p-Amino-D- and -L-PLA were separately coupled to the proteins KLH and 
BSA via diazotization (Figure 4). Thirty mg of/?-amino-D- or -L-PLA were dissolved 
in 2 mL of 0.1 M hydrochloric acid. The solution was cooled on ice, and an equimolar 
amount of sodium nitrite was added while stirring continuously. Sixty mg of protein 
were dissolved in 2 mL of 100 mM borate buffer (pH 8.5) and cooled on ice. After 
ten minutes, the reaction mixture was added dropwise to the cooled protein solution. 
The pH was readjusted to 8.5 by the addition of 0.1 M sodium hydroxide. The 
reaction was allowed to proceed overnight at 4°C. Following diazotization, the 
protein conjugates, p-azo-D- and -L-PLA-KLH, andp-azo-D- and -L-PLA-BSA were 
extensively dialyzed against phosphate-buffered saline (PBS) at 4°C.
Hapten-Carrier Conjugates
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Figure 4: Coupling of p-amino-D- and -L-phenyllactic acid to tyrosine residues of the 
proteins KLH or BSA.
Protein concentrations were determined spectrophotometrically by measuring 
the absorbance at 280 nm. The hapten density was calculated based on the absorbance 
of the protein conjugates at 370 nm using the extinction coefficient of the p-azo-PLA- 
tyramine conjugate, which was determined independently from recrystallized samples.
All animal and cell culture work was performed in accordance with Northern 
Illinois University’s Institutional Research Compliance Guidelines. Institutional 
Animal Care and Use Committee (IACUC) approval was obtained for all work with 
animals (ORC #217 and ORC #258 for rabbits, and ORC #218 and ORC #262 for 
mice, respectively).
Antibody Production
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Polyclonal Antibody Production
For the first immunization (week 0), 100 pg of /?-azo-D-PLA-KLH and p-azo- 
L-PLA-KLH, respectively, in complete Freund’s adjuvant were injected 
subcutaneously at multiple sites in the back of rabbits #73 and #65, respectively. The 
rabbits were each given booster injections of 100 pg ofp-azo-D- or -L-PLA-KLH in 
incomplete Freund’s adjuvant after two weeks. Final immunizations were given after 
four weeks using 100 pg of the respective immunogens in PBS. Interstitial fluid 
samples were taken biweekly beginning with a pre-immunization sample at week 0. 
The samples were collected from wiffle balls implanted under the skin of the rabbits. 
Final blood samples were taken after sacrificing the animals.
Monoclonal Antibody Production
Five eight-week-old BALB/c mice were immunized with p-azo-D-PLA-KLH 
while another five mice were immunized with /?-azo-L-PLA-KLH. Fifty to 100 pg of 
the respective immunogen in complete Freund’s adjuvant were injected 
intraperitoneally. The mice were given booster injections two weeks later with 50-100 
pg of the respective immunogen in incomplete Freund’s adjuvant. Booster injections 
of 50-100 pg of immunogen in PBS were given four weeks after the initial 
immunization and also three to four days before harvesting the spleens. Serum
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samples were collected from the tail of each mouse and tested for antibody 
production and stereoselectivity using competitive and noncompetitive ELISAs. The 
procedure for ELISAs is described in Chapter II in the section Enzyme-Linked 
Immunosorbent Assay. Mice showing good immune responses were chosen for 
monoclonal antibody production.
In preparation for hybridoma production, myeloma cells were grown in RPMI- 
1640 medium until the culture contained 2xl07 cells.
The chosen mouse was anesthetized with carbon dioxide and terminated by 
cervical dislocation. The mouse was then prepped for surgery by disinfection with 
70% ethanol. An incision was made along the left side of the abdomen. The 
abdominal cavity was sprayed with 70% ethanol and allowed to air-dry. The spleen 
was excised and removed with forceps. After the spleen was cleaned of connective 
tissue in a Petri dish filled with RPMI medium, it was transferred to a new Petri dish 
filled with RPMI medium and pulled apart into individual cells with sterile forceps. 
The cells were suspended with a Pasteur pipette and transferred to a sterile Falcon 
tube. Noncellular debris was allowed to settle for ten minutes on ice. The cell 
suspension was then transferred to another Falcon tube. Following centrifugation at 
200 x g for 5 minutes at room temperature, the supernatant was discarded. The cells 
were resuspended in 10 mL of fresh RPMI-1640 medium, and two aliquots of cells 
were removed for a cell count.
Myeloma cells were centrifuged at 200 x g and resuspended in fresh medium at 
a concentration of 107 cells/mL. The splenocytes and myeloma cells were mixed at a
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ratio of 5 to 1. The cells were suspended in 40 mL of medium and then centrifuged 
at 200 x g. The supernatant was discarded. A solution of 1.4 g PEG in 2 mL of 
medium at 37°C was added dropwise. The cell pellet was gently resuspended without 
breaking apart small clumps of cells. RPMI-1640 medium was added dropwise at a 
rate of about 1 mL/min for five minutes. Another 10 mL was added over the next five 
minutes. A final 20 mL was added over another five minutes. The cells were 
centrifuged again and resuspended in 15 mL of RPMI-HAT-HS medium. Following a 
cell count, limiting dilution was performed by adding RPMI-HAT-HS medium to 
achieve a final cell concentration of 5x105 cells/mL. The final cell suspension was 
aliquoted into sterile 96-well polystyrene plates (100 pL/well).
Cells were incubated at 37°C and 5% CO2 . As the medium began to change 
color, the supernatant was collected and screened for antibody production using 
noncompetitive ELISA. Positive clones were transferred to sterile 24-well plates and 
fed with RPMI-HAT-HS medium. Once cells reached high enough density, a portion 
of the cells was frozen while the other was used for subcloning. To freeze cells, 1 mL 
aliquots of cells in medium containing 5% DMSO were transferred to cryovials and 
frozen in a cryo freezing container at -20°C. After 4 hours, the cells were transferred 
to a liquid nitrogen cryo freezer for storage. For subcloning, the cells were diluted by 
a factor of ten, and 100 pL aliquots were pipetted onto sterile 96-well plates. Second 
and third rounds of limiting dilutions were performed to ensure that selected cell lines 
are monoclonal. Monoclonal cell lines were grown in successively larger cell culture
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plates and flasks, respectively, to increase the number of cells. Once monoclonal 
cell lines were established, cells were frozen as described above.
Antibody Purification
Antibody Precipitation
For polyclonal antibodies, interstitial fluid samples were centrifuged at 200 x g 
for 30 minutes while blood samples collected in serum separator tubes were first 
allowed to clot and then centrifuged at 200 x g for 30 minutes. Antibodies from either 
interstitial fluid or serum were precipitated by dropwise addition of saturated 
ammonium sulfate at 4°C to a final concentration of 45%.
Monoclonal antibodies were purified from cell culture supernatant. For that, 
supernatant was first centrifuged to remove any remaining cells and then concentrated 
to a tenth of the original volume using a Centriplus centrifugal filter device with a 
100,000 Da molecular weight cut-off. Antibody was then precipitated from 
concentrated supernatant using 50% aqueous ammonium sulfate.
The precipitated antibody was washed three times with 45% chilled 
ammonium sulfate for polyclonal antibodies and 50% chilled ammonium sulfate for 
monoclonal antibodies. The antibody was then dissolved in PBS and dialyzed 
extensively against the same buffer at 4°C. The purity of the antibody was confirmed
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using sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE), 
which was performed following the manufacturer’s instructions.
Purification of Antibodies Using Melon™ Gel
Antibody samples still containing traces of albumin after ammonium sulfate 
precipitation were purified using the Melon™ Gel IgG purification kit. Serum 
samples from rabbits D#73 and L#65 were diluted 1:10 in Melon™ Gel purification 
buffer following precipitation. Antibody samples from cell culture supernatant were 
first concentrated and precipitated as described above. After adjusting the total protein 
concentration to 15-20 mg/mL using PBS, samples were diluted 1:10 in Melon™ Gel 
purification buffer. Melon™ Gel spin columns were prepared by pipetting 200 pL of 
50% Melon™ Gel slurry at room temperature into the column and washing twice with 
Melon™ Gel purification buffer. Five hundred pL of diluted antibody samples from 
serum or cell culture supernatant were then incubated with the Melon™ Gel slurry in 
spin columns for five minutes at room temperature. The filtrate containing the 
purified antibody was obtained by centrifugation at 5,000 x g for one minute. The 
Melon Gel slurry was then regenerated using the Melon Gel regeneration buffer. 
Larger samples were purified using gravity-flow columns as follows: the Melon™ Gel 
slurry was pipetted into a plastic column and washed with 10 column volumes of 
Melon™ Gel purification buffer. Four milliliters of 50% Melon™ Gel slurry was 
used to purify 40 mL of diluted antibody sample. The antibody sample was applied to
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the column, and 1 mL fractions were collected until absorbance readings at 280 nm 
approached the baseline. The columns were regenerated by washing with 10 column 
volumes of Melon™ Gel regeneration buffer followed by 10 column volumes of 
Melon™ Gel purification buffer. The purity of the antibody was confirmed using 
SDS-PAGE, which was performed following the manufacturer’s instructions.
Affinity Chromatography
Stationary Phase Preparation
Sepharose CL4B was first washed successively with 1:3 (v:v) acetone:water,
1:1 (v:v) acetone:water, 3:1 (v:v) acetone:water, and dry acetone. Two batches of 14 g 
of Sepharose CL4B were each activated with a solution of 1.65 g of DSC and 1.35 g 
of DMAP dissolved in 20 mL of DMF following the procedure of Wilchek and
• 177  •Miron. The reaction was allowed to proceed overnight at 4°C while the Sepharose 
CL4B was kept suspended by end-over-end rotation. Both batches of activated 
stationary phase were successively washed with dry acetone, 5% acetic acid in 1,4- 
dioxane, methanol, and finally isopropyl alcohol. In order to determine the number of 
active groups, an aliquot of 4.0 mg activated Sepharose was hydrolyzed using 1 mL of 
0.25 M ammonium hydroxide. The absorbance of a 1/10 dilution of the aqueous 
phase was then determined spectrophotometrically at 261 nm.122
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In order to immobilize p-amino-D- or -L-PLA via its side chain, 200 mg of 
tyramine in 30 mL of PBS was added to each batch of activated Sepharose and 
allowed to react for 4 hours at 4°C. The stationary phase was then washed 
successively with PBS, 100 mM Tris buffer (pH 7), PBS, 1 M NaCl, and again with 
PBS. Twenty mg of /?-amino-D- or -L-PLA was dissolved in 1 mL of 0.1 M HC1, and 
an equimolar amount of sodium nitrite was added. After ten minutes, the reaction 
mixture was slowly added to the suspension of stationary phase. The pH was adjusted 
to 8.5 with 0.1 M sodium hydroxide. The reaction was allowed to proceed overnight 
at 4°C.
The prepared stationary phase was washed extensively with each of the 
following: PBS, 1 M NaCl, 10 mM triethylamine (TEA), 100 mM TEA, 0.1 M sodium 
hydroxide, 100 mM citric acid, 1M hydrochloric acid, and 6 M guanidinium/HCl. 
Following each of the above washing solutions, the stationary phase was washed with 
water. The stationary phase was stored in water containing 0.01% sodium azide at 
4°C when not in use.
Determination of Elution Conditions
In order to determine suitable elution conditions for particular antibodies, 
microtiter plates were coated and blocked as described in Chapter II in the section 
Enzyme-Linked Immunosorbent Assay. Antibody-containing samples were added to 
the plate (100 pL/well) at a dilution that had previously resulted in absorbance values
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of at least 0.8 as determined by noncompetitive ELISA; the plate was incubated at 
37°C for 2 hours. One of the following solvents was added to each row of the plate: 
PBS, water, 100 mM ammonium hydroxide, 10 mM ammonium hydroxide, 100 mM 
glycine/HCl (pH 2.5), 100 mM citric acid, 10% 1,4-dioxane, 4 M sodium chloride, 6 
M guanidinium/HCl, 1 M acetic acid, 10 mM sodium hydroxide, 10 mM TEA, or 100 
mM TEA. After incubation for ten minutes at room temperature, the plate was 
washed with PBS/Tween 20. Secondary antibody and color formation steps were 
carried out as described in Chapter II in the section Enzyme-Linked Immunosorbent 
Assay.
Affinity Purification of Antibodies
The affinity stationary phase material was washed with 100 mM TEA, water, 
and PBS, respectively. The precipitated and dialyzed antibody was then incubated 
with the affinity stationary phase for two hours at room temperature under continuous 
rotation. The suspension was gently poured into a glass column. The flow-through 
was collected in a 50 mL Falcon tube. The column was then washed thoroughly with 
PBS until no significant levels of protein were detected. This was followed by 
washing the column with PBS containing 1 M sodium chloride to remove any 
nonspecifically bound protein. After washing the column again with PBS, the 
antibody was eluted using 10 mM TEA (pH 12). Fractions of 1 mL collected during 
the elution step were immediately neutralized with 27 pL of 100 mM citric acid.
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Fractions containing significant protein levels were combined and dialyzed 
extensively against PBS. The purified protein solutions were concentrated using 
Centriplus centrifugal filter devices with a 10 kDa molecular weight cut-off. After the 
purification, the stationary phase was washed extensively with 100 mM TEA and with 
water.
Enzyme-Linked Immunosorbent Assay
Ninety-six-well Maxisorp polystyrene microtiter plates were coated with
1 pg/mL solutions of antigen in 50 mM carbonate buffer, pH 9.6. A third of the plate 
was coated with 100 pL/well of either /?-azo-D-PLA-BSA,/>azo-L-PLA-BSA, or 
underivatized BSA. The proteins were allowed to adsorb overnight at 4 °C. After this 
and each of the succeeding steps, plates were washed three times with PBS/Tween20. 
Unoccupied spaces on the plastic surface were blocked with a 1% gelatin solution in 
PBS/0.05% Tween 20 (250 pL/well) by incubation at 37°C for 2 hours. For 
noncompetitve ELISAs, serial dilutions of the antibody-containing samples were 
prepared in PBS. One hundred pL samples were applied per well and incubated for
2 hours at 37°C. After washing, horseradish peroxidase (HRP) labeled goat anti-rabbit 
F(ab’ )2  secondary antibody, for polyclonal antibodies, or HRP labeled goat anti-mouse 
F(ab’ )2  secondary antibody, for monoclonal antibodies, was applied at a 1/10,000 
effective dilution in PBS. One hundred pL was applied per well and the plate was 
again incubated for 2 hours at 37°C. The substrate solution was prepared by adding
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8 mg of OPD and 13 pL of 30% hydrogen peroxide to 20 mL of citrate/phosphate 
buffer. One hundred pL of the OPD solution was added per well; HRP converts OPD 
to 2,2-diamino-azo-benzene, a colored product. The reaction was stopped by 
acidification with 1 N sulfuric acid. Absorbance readings were taken at 492 nm in a 
plate reader.
For competitive ELIS As, the plates were coated and blocked as described 
above for noncompetitive ELIS As using either p-azo-D- or -L-PLA-BSA for anti-D- 
AHA antibodies and anti-L-AHA antibodies, respectively. Serial dilutions of 
competitor were applied in triplicate onto the plate (50 pL/well in PBS), followed by 
addition of antibody at a constant concentration in PBS (50 pL/well). The secondary 
antibody and color formation steps were carried out as described for noncompetitive 
ELISAs.
ELISAs using the anti-AA antibodies were performed following the same 
protocols except that/?-azo-D-Phe-BSA, ;?-azo-L-Phe-BSA, and underivatized BSA 
were used as coatings.
Isotype Determination
Ninety-six-well MaxiSorp polystyrene microtiter plates were coated and 
blocked as described for noncompetitive ELISAs. One hundred pL/well of 
monoclonal antibody to be tested in PBS were applied to twelve wells at a dilution that 
had previously resulted in absorbance values of at least 0.8; plates were incubated for
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2 hours at 37°C. After washing three times with PBS/Tween 20, each of the six 
isotype-specific reagents from the isotyping kit was applied in duplicate (100 pL/well; 
1/500 in PBS). The plate was incubated for 30 minutes at room temperature and then 
washed three times with PBS/Tween 20. One hundred pL of peroxidase-labeled 
donkey anti-goat antibody were added to each well at a dilution of 1/5,000 in PBS and 
incubated for 30 minutes at room temperature. The color formation step was carried 
out using OPD as substrate following the procedure described for noncompetitive 
ELISAs.
Fluorescence Immunoassay 
Development of a Fluorescence Immunoassay Using ELISA
Ninety-six-well Maxisorp polystyrene microtiter plates were coated with 100 
pL/well of a mixture of /7-azo-D-PLA-BSA and p-azo-D-Phe-BSA. Both of the 
antigens were in 50 mM carbonate buffer, pH 9.6; each antigen was at a concentration 
of 1 pg/mL. The proteins were allowed to adsorb overnight at 4 °C, and plates were 
washed and blocked as described for noncompetitive ELISAs. Serial dilutions of 
competitor were applied in triplicate onto the plate (50 pL/well in PBS alone or in 
PBS containing 10 mM D-Phe or 10 mM D-PLA), followed by addition of antibody at 
a constant concentration in PBS (50 pL/well). Antibodies used were anti-D-AHA 
polyclonal antibody from rabbit #73 (anti-D-AHA 73), the anti-D-amino acid antibody
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secreted by the clone 67.36 (anti-D-AA 67.36), or a mixture of both antibodies as 
indicated in the section Fluorescence Immunoassay Development in Chapter III. The 
secondary antibody and color formation steps were carried out following the same 
procedure as described for noncompetitive ELISAs.
Development of a Fluorescence Immunoassay Using 
Fluorophore-Labeled Secondary Antibodies
Reacti-bind™ white opaque 96-well plates were coated and blocked as 
described for noncompetitive ELISAs. Serial dilutions of anti-D-AHA 73 (100 
pL/well) were applied and incubated for 2 hours at 37°C. After washing the plate, 
goat anti-rabbit IgG Dylight™ 547-conjugated antibody was added onto the plate at a 
dilution of 1:250 in PBS (100 pL/well). The plate was incubated at room temperature 
for 30 minutes. The plate was again washed three times with PBS/Tween 20 and then 
rinsed with PBS. One hundred pL/well of PBS were applied onto the plate prior to 
measuring. The fluorophore was excited at 557 nm and fluorescence emission was 
measured at 570 nm utilizing the “fluorescence mode” of the plate reader.
The same procedure was used for anti-D-AA 67.36 except that plates were 
coated with the p-azo-Phe-BSA conjugates, and goat anti-mouse IgG Dylight™ 647- 
conjugated antibody was used as the secondary antibody. The fluorophore was 
excited at 652 nm; fluorescence emission was measured at 673 nm.
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For competitive immunoassays, the plates were again coated and blocked as 
described for noncompetitive ELISAs using either/?-azo-D-PLA-BSA or/?-azo-D-Phe- 
BSA for detection of anti-D-AHA 73 and anti-D-AA 67.36, respectively. Serial 
dilutions of competitor were applied in triplicate onto the plate (50 pL/well), and 
antibody at a constant concentration in PBS was applied (50 pL/well). The washing 
and secondary antibody steps were carried out using the same procedure as described 
for noncompetitive fluorescence immunoassays.
Competitive fluorescence immunoassays were then repeated using both anti-D- 
AHA 73 and anti-D-AA 67.36 for the simultaneous detection of D-Phe and D-PLA. 
Plates were coated with a mixture of/j-azo-D-PLA-BSA and p-azo-D-Phe-BSA with 
each antigen at a concentration of 1 pg/mL in carbonate buffer. The plates were 
washed and blocked as described for noncompetitive ELISAs. Mixtures of serial 
dilutions of D-Phe and D-PLA were both applied in triplicate onto the plate (25 
pL/well for each competitior). A mixture of anti-D-AHA 73 and anti-D-AA 67.36 at a 
constant concentration was then applied to the plate (50 pL/well). After washing, a 
mixture of goat anti-mouse IgG Dylight™ 647-conjugated antibody and goat anti­
rabbit IgG Dylight™ 547-conjugated antibody (1:250 in PBS; 100 pL/well) was then 
applied onto the plate. The plate was again washed three times with PBS/Tween 20 
and then rinsed with PBS. One hundred pL/well of PBS were applied to the plate 
prior to measuring. The plate was first measured by exciting the Dylight™ 647 
fluorophore at 652 nm and measuring fluorescence emission at 673 nm in order to 
detect the interaction between anti-D-AHA 73 and D-PLA. The plate was then
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remeasured by exciting the Dylight™ 547 fluorophore at 557 nm and measuring 
fluorescence emission at 570 nm in order to detect the interaction between anti-D-AA 
67.36 and D-Phe.
Conjugation of Fluorophores to Antibodies
Four antibodies were selected for conjugation to four different fluorophores: 
the anti-D-AHA antibody secreted by the clone 8E10.9 (anti-D-AHA 8E10.9), anti-D- 
AA polyclonal antibody, the anti-L-AHA polyclonal antibody from rabbit #65 (anti-L- 
AHA 65), and the anti-L-amino acid antibody secreted by the clone 18.3 (anti-L-AA 
18.3), respectively. The compounds used for labeling the aforementioned antibodies 
were DyLight™ 547 NHS ester, DyLight™ 647 NHS ester, DyLight™ 800 NHS 
ester, and DyLight™ 490 NHS ester, respectively. Antibodies were first dialyzed 
against 50 mM sodium borate buffer, pH 8.5. Labeling was then carried out as 
follows: a 15-fold excess of DyLight™ 547 (24.3 pL of a 10 mg/mL solution in 
DMF) was added to 1.5 mL of anti-D-AHA 8E10.9 (at 2.25 mg/mL). A 7.5-fold 
excess of DyLight™ 647 (12.6 pL of a 10 mg/mL solution in DMF) was added to 1.5 
mL of the anti-D-AA polyclonal antibody (at 2.25 mg/mL). A 6-fold excess of 
DyLight™ 800 (15.0 pL of 10 mg/mL solution in DMSO) was added to 1 mL anti-L- 
AHA 65 (at 1.4 mg/mL). A 5-fold excess of DyLight™ 490 (21 pL of a 10 mg/mL 
solution in DMSO) was added to 1.5 mL of anti-L-AA 18.3 (at 2.1 mg/mL). The 
solutions were briefly vortexed and the reactions were allowed to proceed at 4°C for 2
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hours under continuous rotation. The reactions were carried out in the dark with all 
microcentrifuge tubes wrapped in aluminum foil to protect the fluorophores from 
light. After completion of the reactions, the solutions were dialyzed extensively 
against PBS in 2 L Erlenmeyer flasks wrapped in foil in order to remove unreacted 
dyes.
Antibody concentrations were determined spectrophotometrically by 
measuring the absorbance at 280 nm. The dye-to-protein ratio was calculated based 
on the absorbance of the protein conjugates at the following wavelengths: 494 nm for 
the DyLight™ 490-labeled anti-L-AA 18.3, 547 nm for the DyLight™ 547-labeled 
anti-D-AHA 8E10.9, 647 nm for the DyLight™ 647-labeled anti-D-AA polyclonal 
antibody, and 774 nm for the DyLight™ 800-labeled anti-L-AHA 65. The extinction 
coefficients of the respective dyes were taken from the manufacturer’s product 
information.
Noncompetitive Fluorescence Immunoassay
Reacti-bind™ white opaque 96-well plates were coated and blocked as 
described for noncompetitive ELISAs. Serial dilutions of the DyLight™ 490-labeled 
anti-L-AA 18.3, the DyLight™ 547-labeled anti-D-AHA 8E10.9, the DyLight™ 647- 
labeled anti-D-AA polyclonal antibody, or the DyLight™ 800-labeled anti-L-AHA 65 
were applied onto the plate (100 pL/well) and incubated for 1 hour at room 
temperature. The plate was washed three times with PBS/Tween 20 and then rinsed
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with PBS. One hundred pL/well of PBS were applied to the plate prior to 
measuring. Excitation and emission wavelengths were as follows: DyLight™ 490: 
491/518 nm, DyLight™ 547: 557/570 nm, DyLight™ 647: 652/673 nm, and 
DyLight™ 800: 770/794 nm.
Competitive Fluorescence Immunoassay
The plates were coated and blocked as described for noncompetitive ELISAs 
using p-azo-D-PLA-BSA for DyLight™ 547-labeled anti-D-AHA 8E10.9,/?-azo-D- 
Phe-BSA for DyLight™ 647-labeled anti-D-AA polyclonal antibody, /?-azo-L-PLA- 
BSA for DyLight™ 800-labeled anti-L-AHA 65, and/>-azo-L-Phe-BSA for DyLight™ 
490-labeled anti-L-AA 18.3. Serial dilutions of competitors were applied in triplicate 
to each plate (50 pL/well), and the respective labeled antibody was applied at a 
constant concentration (in PBS, 50 pL/well). The plates were washed three times with 
PBS/Tween 20 and then rinsed with PBS. One hundred pL/well of PBS were applied 
to the plate prior to measuring.
For the simultaneous detection of AA and AHA enantiomers, a mixture of p- 
azo-D-PLA-BSA, />azo-D-Phe-BSA, p-azo-L-PLA-BSA, and p-azo-L-Phe-BSA was 
used to coat Reacti-bind™ white opaque 96-well microtiter plates (100 pL/well). All 
four of the antigens were in 50 mM carbonate buffer pH 9.6; each antigen was at a 
concentration of 1 pg/mL. The proteins were allowed to adsorb overnight at 4 °C, and 
plates were washed and blocked as described for noncompetitive ELISAs. Mixtures
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of serial dilutions of D- and L-Phe and D-and L-PLA were applied in triplicate onto 
the plate (12.5 pL/well in PBS for each competitor) and antibody solution containing 
all four fluorophore-conjugated antibodies in PBS was applied at a constant 
concentration (50 pL/well). The plates were washed three times with PBS/Tween 20 
and then rinsed with PBS. One hundred pL/well of PBS were applied to the plate 
prior to measuring. Plates were measured as described for the noncompetitive 
fluorescence immunoassay.
Chiral Immunoaffinity Chromatography
PEEK tubing (200 mm x 0.75 mm i.d.) was packed with 100-3 Nucleosil silica 
using an Alltech slurry packer fitted with a 20 mL reservoir. Ethanol (95%) was used 
as both the slurry and packing solvent. The pressure was gradually increased to 200 
bars; packing continued until a constant flow rate was achieved. The column was then 
flushed successively with 95% ethanol, acetone, and dry acetone using a syringe 
pump. The silica was activated in situ with DSC according to the method of Wilchek 
and Miron.122 DSC (84.5 mg) and DMAP (62.4 mg) in DMF (960 pL) were pumped 
onto the column at 1 pL/min. The column was flushed with dry acetone, 5% acetic 
acid in 1,4-dioxane, methanol, isopropyl alcohol, and briefly with water before the 
addition of antibody. Anti-D-AHA 73 (1.4 mL at 4 mg/mL in PBS) was applied to the 
column. Initially antibody was applied at 5 pL/min for 30 minutes and the remaining 
antibody was applied at 1 pL/min. The column was then flushed with PBS and 1M
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NaCl to remove unbound antibody. The amount of immobilized antibody was 
estimated to be 80% of the total antibody applied by calculating the difference 
between the amount of antibody applied and the amount of antibody collected after 
immobilization as determined from UV-absorbance measurements at 280 nm.
Separations were carried out at room temperature using PBS as mobile phase. 
Five microliters of nonracemic mixtures of PLA were injected. The 100 pL/min flow 
rate was split before the injector using a back-pressure regulator. Other conditions are 
given in the section Chiral Immunoaffinity Chromatography in Chapter III.
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CHAPTER III 
RESULTS AND DISCUSSION
Synthesis and Characterization of Immunogens
Antibodies, an element of the humoral immune system of vertebrates, are a 
group of glycoproteins present in the serum and tissue fluids of all mammals and are 
secreted by B-lymphocytes. Although the primary purpose of antibody production is 
to protect an organism against pathogens, antibody production can be initiated against 
virtually any molecule as long as it contains a distinct antigenic site, called epitope, 
and/or can be coupled to a carrier molecule. Antibodies with desired binding 
properties can be produced against a wide range of compounds, which is essential for 
their application in bioanalytical techniques such as immunoassays.
Selection or synthesis of an appropriate immunogen is the first step in the 
production of antibodies. Molecules larger than 5 kDa are usually good immunogens 
as long as they are recognized as being foreign to the host animal. Thus, proteins and 
polypeptides with larger molecular weights are generally immunogenic and can be 
injected without any further modification. However, small molecules, i.e., those with 
less than 1 kDa, typically cannot elicit an immune response by themselves. In the 
early 1900s, Landsteiner realized that such molecules, called haptens, could be
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rendered immunogenic if they are covalently linked to a carrier molecule such as a 
protein. Landsteiner, in his original experiments, prepared synthetic antigens by 
coupling diazonium compounds to serum proteins via tyrosine and histidine residues 
on the protein. Rabbits inoculated with the (artificially) prepared azo-proteins 
produced antibodies that recognized the attached hapten as detected by 
immunoprecipitation.51
The overall principles for the production of anti-hapten antibodies have 
remained essentially unchanged since Landsteiner’s work, although, since then, 
various other reactions for the conjugation of haptens to proteins have been 
established.123,124 As any conjugation strategy must preserve the “immunogenicity” of 
the hapten, the point of attachment between hapten and carrier is critical. The 
specificity of anti-hapten antibodies, as Landsteiner demonstrated, is directed 
primarily toward the part of the hapten farthest away from the point of linkage to the 
carrier protein.51 This principle of hapten accessibility was further elucidated by 
Michael Sela et al., who showed that, e.g., oligopeptides must be readily accessible on 
the surface and not in the interior of hapten-carrier conjugates.125,126
Similar observations were made with antibodies against protein antigens. For 
example, in myoglobin the antigenic regions are located at the areas of the molecule 
which are exposed on the outer surface.127,128 Another example is lysozyme, in which 
the loop region, which is an immunodominant determinant in the molecule,129'131 is 
exposed on the surface of the protein.132 Thus, the fact that antibodies recognize 
epitopes on the surface must be considered in the design and synthesis of
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immunogens. If antibodies are needed to discriminate between closely related 
compounds, functional groups on the hapten essential for distinguishing the molecule 
from other analogs and precursors should not be used for conjugation to carrier 
proteins.133 Conversely, if cross-reactive antibodies are desired, the shared functional
133groups on the hapten should be exposed on the surface of the immunogen.
Similarly, a chiral hapten should be conjugated to a carrier at a site away from 
the asymmetric center to optimize the stereospecificity of the antibodies produced.134 
In this way, the asymmetric center is exposed on the surface of the immunogen. 
Additionally, for chiral haptens, four possible combinations exist: either the racemate 
or the individual stereoisomers may be used for both the immunogen and for the 
screening assay, or alternatively, the racemate may be used for either the immunogen 
or the screening assay and the individual stereoisomers may be used for the other.134 
Regardless of whether racemic or enantiomerically pure haptens are used for the 
immunogen, a heterogeneous population of antibodies will be produced, which may 
include a range of selective and cross-reactive antibodies against the hapten in 
addition to antibodies which recognize the carrier. Racemic haptens are typically 
preferred for the production of antibodies that must recognize both enantiomers (e.g., 
for immunoassays of racemic drugs).134 Alternatively, analogues which lack a chiral 
center may be used as haptens to produce antibodies for racemic assays.134 Racemic 
haptens may also result in stereoselective antibodies; however, enantiomerically pure 
haptens improve the probability of producing stereoselective antibodies.134135 
Landsteiner, who first produced stereoselective antibodies, conjugated, e.g., D-
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tartanilic acid, a derivative of D-tartaric acid, to a protein to produce antibodies 
which could discriminate between D- and L- tartaric acid.51
Since a primary objective of this dissertation was to produce antibodies which 
stereoselectively bind to AHAs, the AHA hapten was conjugated to the carrier in such 
a way that the hydroxyl/carboxyl/hydrogen triad about the a-carbon is oriented on the 
outside of the immunogen. Thus, the shared functional groups of AHAs are exposed 
on the surface of the immunogen, which, ideally, results in antibodies that cross-react 
with a wide range of AHAs. Since these same functional groups are also unique to 
AHAs, the resulting antibodies should be specific to this group of compounds. 
Additionally, the probability of producing stereoselective antibodies is increased by 
exposing the chiral center of the hapten on the surface of the immunogen and by using 
enantiomerically pure haptens.
While a wide range of coupling chemistries may be used for conjugation of 
haptens to carrier proteins, the conjugation should be simple, reproducible, and result 
in an optimal presentation of the hapten on the surface of the immunogen.124 
Diazotization, a process by which an aromatic primary amine is converted to a 
diazonium compound, was used for preparation of the immunogens. In diazotization, 
sodium nitrite is added to a solution of the amine in aqueous acid solution at 0-5°C.136 
Reaction of the amine with nitrous acid gives a nitrosamine; tautomerization and loss 
of water lead to the diazonium cation, which is stabilized by delocalization of the 
positive charge at the ortho- and para-carbon atoms of the ring. The great 
importance of diazonium compounds in immunogen preparation lies in their ability to
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couple to tyrosine or histidine residues on proteins. The diazotization reaction 
proceeds by electrophilic attack of the diazonium group at the electron-rich points on
the target molecules to yield an arylazo group at the position para or ortho to hydroxyl
1or amino groups. Diazotization results in an oriented presentation of haptens with 
excellent yields. Diazotization is also a relatively simple chemistry to use— 
particularly as no protecting groups are needed. The resulting azoproteins are deeply 
colored, which can provide visual confirmation of the completion of the reaction. This 
approach was previously used by Hofstetter et al. to produce stereoselective antibodies 
to a-amino acids.35,59 Enantiomerically pure /?-amino-D- or -L-Phe were coupled to 
KLH via diazotization, and the resulting conjugates were used as immunogens for the 
production of both polyclonal and monoclonal antibodies.59,60 In this research, 
immunogens were produced by coupling the analogous p-amino-PLA to KLH. p- 
Amino-D- and -L-PLA were not commercially available and, therefore, were 
synthesized from D- and L-PLA, respectively, as described in Chapter II, section 
Synthesis of Immunogens.
In addition to being used for the production of the immunogens, p-amino-D- 
and -L-PLA, and their precursors, />-nitro-D- and -L-PLA were also used as 
competitors in competitive ELISAs as described in Chapter II, section Enzyme-Linked 
Immunosorbent Assay.
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p-Nitro-Phenvllactic Acid
The nitration of both D- and L-PLA, which was performed as described in 
Chapter II, section Synthesis of Immunogens, is a typical electrophilic aromatic 
substitution reaction. The nitronium ion is created by protonation of the hydroxyl 
group of nitric acid by sulfuric acid followed by the loss of water. The nitronium ion, 
an excellent electrophile, then reacts with phenyllactic acid forming an intermediate 
sigma complex, which results in loss of a proton, yielding p-nitro-D- and -L-PLA, 
respectively. Because alkyl groups are ring-activating substituents (ortho- and para- 
directing), nitration of PLA at the ortho and para positions are favored. The para- 
substituted product, however, is the major product because the ortho-substituted 
product is sterically hindered. The synthesis ofp-nitro-PLA was confirmed by 'H 
NMR, IR, and mass spectrometry.
*H NMR spectra ofp-nitro-D- and -L-PLA were recorded on a 200 MHz 
instrument using DMSO-d6 as solvent. The results in ppm for p-nitro-D-PLA are as 
follows: 8.16 (2H, d, J=7.9 Hz, 6-H and 8-H), 7.56 (2H, d, J=7.6 Hz, 5-H and 9-H), 
4.25 (1H, dd, J=8.3 Hz, 4.3 Hz, 2-H), 3.10 (1H, d, J=4.2 Hz, 3a-H), 2.98, (1H, d, J=8.4 
Hz, 3b-H), 2.52 (1H, s, 2-OH). Thep-nitro-L-PLA results are as follows: 8.16 (2H, d, 
J=7.8 Hz, 6-H and 8-H), 7.54 (2H, d, J=8.3 Hz, 5-H and 9-H), 4.25 (1H, dd, J=8.4 Hz, 
4.3 Hz, 2-H), 3.10 (1H, d, J=4.2 Hz, 3a-H), 2.98, (1H, d, J=8.3 Hz, 3b-H), 2.56 (1H, s,
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2-OH). Two doublets in the aromatic region (8.16 and 7.5 ppm), which are 
characteristic of para-substituted benzene, were observed in the spectra of both 
enantiomers.
The presence of the nitro group was also confirmed by IR. The -N-0 
symmetric stretch was found at 1348 cm'1 and the -N-0 asymmetric stretch was found 
at 1524 cm'1 for p-nitro-D-PLA. The -O-H stretch was found at 3113 cm’1. For p- 
nitro-L-PLA, the -N-0 symmetric stretch was found at 1344 cm'1, the -N-0 
asymmetric stretch was found at 1516 cm'1, and the -O-H stretch was found at 3119 
cm'1.
The purified p-nitro-D- and -L-PLA are both dark yellow. The melting point, 
optical rotation and mass (as determined by ESI-MS) are given in Table 1. The 
calculated mass of p-nitro-PLA is 211.05.
Table 1: Physical properties of synthesized p-nitro-phenyllactic acid
melting point (°C) Observed m/z [a]o25
p-nitro-D-PLA 135-138 210.9 +24.3°
p-nitro-L-PLA 133-137 210.9 -23.7°
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The catalytic hydrogenation of p-nitro-D- and -L-PLA to p-amino-D- and -L- 
PLA was carried out as described in Chapter II, section Synthesis of Immunogens.
The hydrogenation reaction proceeds readily at room temperature and low pressures of 
hydrogen in the presence of a palladium-charcoal catalyst. The synthesis of p-amino- 
D- and -L-PLA was confirmed by 'H NMR, IR, mass spectrometry, and reaction with 
ninhydrine.
'H NMR spectra of p-amino-D- and -L-PLA were recorded in a 200 MHz 
instrument using DMSO-d6 as solvent. The p-amino-D-PLA results in ppm are as 
follows: 7.01 (2H, d, J=8.4 Hz, 6-H and 8-H), 6.71 (2H, d, J=8.4 Hz, 5-H and 9-H), 
4.05 (1H, dd, J=7.8 Hz, 4.9 Hz, 2-H), 2.78 (1H, d, J=7.5 Hz, 3a-H), 2.64 (1H, d, J=7.4 
Hz, 3b-H), 2.52 (1H, s, 2-OH). The results for p-amino-L-PLA in ppm are as follows: 
7.01 (2H, d, J=8.4, 6-H and 8-H), 6.71 (2H, d, J=8.4, 5-H and 9-H), 4.05 (1H, dd, 
J=7.8, 4.9, 2-H), 2.78 (1H, d, J=7.5, 3a-H), 2.64, (1H, d, J=7.4, 3b-H), 2.52 (1H, s, 2- 
OH). The characteristic two doublets of /^-substituted benzene are shifted downfield 
from those of the p-nitro-D- and -L-PLA in both spectra.
IR results confirmed the presence of the amino group for both the p-amino-D- 
and -L-PLA. The -C-N stretch was found at 1740.99 cm'1; the -O-H stretch was found 
at 3144.29 cm'’for the p-amino-D-PLA. For thep-amino-L-PLA, the -C-N stretch was 
found at 1741.45 cm'1 and the -O-H stretch was found to be 3221.82 cm'1.
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The presence of the amino group was also confirmed qualitatively by 
reaction with ninhydrine. The purified p-amino-D- and -L-PLA are both light yellow.
The melting point, optical rotation and mass (as determined by ESI-MS) are 
given in Table 2. The calculated mass ofp-amino-PLA is 181.07.
Table 2: Physical properties of synthesized p-amino-phenyllactic acid
Melting point (°C) Observed m/z W d25
p-amino-D-PLA 180-184 182 +42.3°
p-amino-L-PLA 181-185 182 -40.9°
Synthesis and Characterization of Hapten-Protein Conjugates
The synthesized p-amino-D- or -L-PLA was separately coupled to the proteins 
KLH and BSA via diazotization. For that, the p-amino-D- or -L-PLA was reacted with 
nitric oxide to form the diazonium salt of PLA. Nitric oxide is obtained by reaction of 
sodium nitrite with hydrochloric acid to form nitrous acid, which degrades to nitric 
oxide. The diazonium salt of PLA, a good electrophile, reacts primarily with tyrosine 
residues on the KLH or BSA under basic conditions to formp-azo-PLA-BSA or -KLH 
conjugates. p-Azo-D- and -L-PLA-tyramine conjugates were synthesized following
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the same procedure. The KLH conjugates were used for the immunization of both 
rabbits and mice, whereas the BSA conjugates were used in immunoassays as solid- 
phase coatings.
In order to determine the hapten density, i.e., the hapten-to-protein ratio, the 
appropriate extinction coefficient was determined from p-azo-D- and -L-PLA-tyramine 
conjugates. The p-azo-D- and -L-PLA-tyramines were dark red in color with an 
extinction coefficient of e=10,000 cnf'M"1 at 370 nm. Using this value, the hapten-to- 
protein ratios presented in Table 3 were determined as described in Chapter II, section 
Synthesis of Immunogens.
Table 3: Hapten densities





* expressed per subunit of KLH (approximate MW = 51,000)
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It is known from the pioneering work of Landsteiner that the hapten density 
affects an animal’s immune response. Generally, with too few haptens, only 
antibodies recognizing the carrier used for immunization are produced, whereas with
1 37too many haptens, the overall immune response may decrease. Other researchers 
have found that higher hapten densities may produce a fast, primarily IgM-based 
immune response, and those antibodies often have a weaker affinity. Conversely, a 
lower hapten density can result in antibodies with higher affinity, although the
1 3 R  1 3 0immune response may be slower. ’
Production and Characterization of Polyclonal Antibodies 
Immune Response
The p-azo-D- and -L-PLA-KLH immunogens were used to inoculate rabbits 
#73 and #65, respectively, as described in Chapter II, section Antibody Production. 
Stereoselective antibodies were detected in noncompetitive ELISAs using the BSA 
conjugates of the p-amino-D- or -L-PLA as solid-phase coatings. It was found that 
antibodies from rabbit #73 (anti-D-AHA 73) bound to the p-azo-D-PLA-BSA coating 
while antibodies from rabbit #65 (anti-L-AHA 65) bound to the p-azo-L-PLA-BSA 
coating. No detectable binding to the opposite enantiomer or to BSA was observed in 
noncompetitive ELISAs using antibodies from either rabbit. Figure 5 shows time- 
dependent immune response plots for interstitial fluid samples determined at 1/10,000
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Figure 5: Immune responses of rabbits a) #73 and b) #65 following three injections 
withp-azo-D- and -L-PLA-KLH, respectively, in complete Freund’s adjuvant, 
incomplete Freund’s adjuvant, and PBS, respectively, at biweekly intervals (arrows). 
Antibody-containing interstitial fluid was tested in noncompetitive ELISA at 1/10,000 
dilution on three different coatings, namely, p-azo-D-PLA-BSA ( • ) ,  p-azo-L-PLA- 
BSA (O), and BSA (A).
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dilution for rabbits #73 and #65, respectively. Samples of interstitial fluid were 
obtained on a biweekly basis beginning with a pre-immunization sample of interstitial 
fluid obtained from each rabbit just prior to inoculation with the immunogen in CFA. 
At weeks 2 and 4, booster injections of immunogen in IFA and in PBS, respectively, 
were given. As expected, pre-immunization samples (week 0) showed no detectable 
immune response in noncompetitive ELISAs. However, by week 6, both rabbits #73 
and #65 showed significant, stereoselective immune responses, which peaked by week 
14 and 12, respectively.
The titer of each polyclonal antibody was determined by noncompetitive 
ELISAs for samples collected on a biweekly basis for 40 weeks. Sample binding 
curves of combined samples of interstitial fluid collected at weeks 6-18 were 
determined using noncompetitive ELISAs for both antibodies and are presented in 
Figure 6. The titers for these combined samples were found to be 1/100,000 for both 
anti-D-AHA 73 and anti-L-AHA 65.
Purification of Polyclonal Antibodies
Precipitation is commonly used as an initial step in the purification of proteins 
from crude mixtures. If a precipitating agent, such as saturated ammonium sulfate, is 
added to a crude mixture, the ammonium and sulfate ions compete with the protein for
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Figure 6: Noncompetitive ELISA results for a) anti-D-AHA 73 and b) anti-L-AHA 65 
using interstitial fluid samples collected at weeks 6-18. p-Azo-D-PLA-BSA (•),/? - 
azo-L-PLA-BSA (O), and BSA were used as solid-phase coatings. At each dilution, 
the values obtained with the BSA coating were subtracted from those obtained on the 
other two coatings. Data points represent means of triplicate determinations. Error 
bars are obscured by symbols.
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water molecules, which decreases the solubility of the protein and results in 
precipitation.140 Polyclonal antibodies precipitate when the concentration of 
ammonium sulfate reaches approximately 45%, whereas most other proteins found in 
serum or interstitial fluid remain in solution. Optimal separation is achieved by slow, 
dropwise addition of a saturated solution of ammonium sulfate. Typically, other 
proteins coprecipitate with antibodies; however, here the precipitate from interstitial 
fluid contained only antibodies as determined by SDS-PAGE. The procedure for 
antibody precipitation is found in Chapter II, section Antibody Purification. Figure 7 
shows a nonreducing SDS-PAGE gel of anti-D-AHA 73 from interstitial fluid before 
and after ammonium sulfate precipitation; the nonreducing SDS-PAGE gel of the anti- 
L-AHA 65 was comparable.
Because antibody samples obtained from sera still contained impurities, they 
were further purified using the Melon™ Gel purification kit (Figure 8). More 
commonly, antibodies have been purified by ion-exchange, size-exclusion, or affinity 
chromatography. In size-exclusion chromatography, porous beads are used to separate 
molecules on the basis of size. In ion-exchange chromatography, molecules are 
separated on the basis of charge using either a cationic or anionic exchange resin. Ion- 
exchange and size-exclusion chromatography are used to purify a wide range of 
proteins, and separation conditions must be determined experimentally for optimal 
purifications. Because size-exclusion and ion-exchange resins do not specifically bind 
antibodies, antibodies may co-elute with other proteins.






Figure 7: Nonreducing sodium dodecyl sulfate-polyacrylamide gel electrophoresis of 
interstitial fluid was used to determine the purity of samples before and after 
precipitation. Unpurified interstitial fluid (lane 1) was precipitated with 45% saturated 
ammonium sulfate. The precipitate only contained antibodies (lane 4). All 
contaminant proteins remained in the supernatant (lane 2), which contained no 
residual antibody. Lane 3 contains the MW marker and lane 5 is a positive control.
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Figure 8: Nonreducing sodium dodecyl sulfate-polyacrylamide gel electrophoresis of 
serum was used to determine the purity of samples before and after precipitation and 
Melon™ Gel purification. Unpurified serum was precipitated with 45% saturated 
ammonium sulfate. The precipitate contained impurities (lane 1). The impurities 
were removed by further purification using Melon™ Gel (lane 2) followed by affinity 
purification (lane 3). Lane 4 is a positive control and lane 5 is the marker.
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In contrast, proteins A, G, L, and, more recently, recombinant protein A/G 
are specifically used to purify immunoglobulins in affinity chromatography. Protein 
L, from the bacterium Peptostreptococcus magnus, binds to the light chains of most 
immunoglobulins.141 Protein A, from Staphylococcus aureus, binds to the Fc region 
of immunoglobulins, primarily IgGs.142 While native protein G is isolated from group 
G Streptococci, recombinant protein G is typically used for the purification of 
immunoglobulins. Protein G binds to the immunoglobulin Fc regions from a wider 
range of species than protein A and, in the recombinant version, has had the cell 
surface and albumin binding sites removed.143,144 Protein A/G is a recombinant 
protein containing the Fc binding domains from both proteins A and G and, therefore, 
binds an even wider range of immunoglobulins, including all human and mouse IgG 
subclasses.144 Harsh conditions are often required to elute the antibodies from protein 
A, G, L or A/G columns, which may denature the antibody. This procedure may also 
add a time-consuming dialysis or desalting step.
The Melon™ Gel, however, is designed to bind common serum proteins such 
as albumin and transferrin, but not antibodies. Antibodies can therefore be rapidly 
purified, e.g., in spin columns, without harsh denaturing conditions using a mild buffer 
at physiological pH. The purification buffer is also suitable for storage and 
downstream applications.
While ammonium sulfate precipitation and Melon™ Gel purification remove 
unwanted proteins from the antibody, the samples may still contain an array of 
antibodies against many different antigens. Affinity purification can be used to isolate
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only those antibodies which bind to the desired antigen. In 1968, Pedro 
Cuatrecases, Chris Anfinsen, and Meir Wilchek first introduced affinity 
chromatography, which utilizes the immense power of biorecognition as a means of 
purification.145 They successfully purified three enzymes, namely staphylococcal 
nuclease, a-chymotrypsin, and carboxypeptidase A, by immobilizing their respective 
inhibitors to activated Sepharose. Each of the proteins was eluted using acetic acid at 
pH 3.
Since that time, affinity purification has become a powerful tool in biomedical 
research and biotechnology as a separation system that exploits interactions between a 
protein and a specific ligand (e.g., enzyme-inhibitor, antibody-antigen, receptor- 
hormone, etc.) to isolate either the protein or its ligand. First, one of the two binding 
partners is immobilized. Second, the affinity matrix is equilibrated in a mild buffer 
such as PBS and the complementary binding partner is allowed to bind. Unbound and 
nonspecifically adsorbed material is then washed from the column with buffer. 
Alternatively, higher ionic strength buffer may be used for a more stringent washing. 
Finally, the bound analyte is eluted specifically using a competitive ligand, or 
nonspecifically by changing pH, ionic strength, or polarity. Commonly used elution 
buffers include acids, bases, organic solvents, and chaotropic salts. While specific 
elution with competitive ligands may avoid protein denaturation, it may be impractical 
or prohibitively expensive. Nonspecific elution conditions, however, may be 
ineffective or may denature proteins. To minimize denaturation, purified proteins 
should be neutralized immediately after elution and then dialyzed against a mild
R ep ro d u ced  with p erm issio n  o f  th e  copyrigh t ow n er. Further reproduction  prohibited w ithout p erm ission .
63
buffer. Matricies containing proteins should also be washed with a mild buffer 
immediately after the purification.
For the purification of the polyclonal antibodies against D- or- L-AHAs, the 
hapten, i.e., p-amino-D- or -L-PLA, was immobilized on cross-linked Sepharose using 
the same chemistry (that is, diazotization) used for preparation of the immunogen. 
First, tyramine was immobilized on activated cross-linked Sepharose. The diazonium 
salt of/j-amino-D- or -L-PLA was then reacted with the tyramine moiety to form a p- 
azo-D- or -L-PLA-tyramine conjugate. Since anti-hapten antibodies cannot be raised 
against free low-molecular weight haptens, even antibodies which are specific to the 
hapten may recognize a portion of the carrier or a linker that may have been used. 
Thus, if the hapten is immobilized on an affinity stationary phase using a different 
chemistry than that used for the immunogen production, the amount of specific 
antibody purified will most likely decrease. However, if the immunogen itself is used 
for affinity purification, nonspecific antibodies recognizing the carrier may also bind 
to the affinity stationary phase. Thus, the hapten should be immobilized on the 
stationary phase in a way that maximizes the amount of specific anti-hapten antibody 
and minimizes the amount of nonspecific antibody. Additionally, proteins should be 
avoided in stationary phase preparation because they are susceptible to denaturation 
and bacterial degradation. The p-azo-D- or -L-PLA-tyramine Sepharose stationary 
phase used here can specifically purify antibodies that recognize the hapten from those 
that may recognize the KLH carrier or other antigens. The stationary phase is also 
extremely durable because it contains no proteins. One batch of stationary phase was
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prepared for purification of anti-D-AHA antibodies while another batch was made 
to purify anti-L-AHA antibodies as described in Chapter II, section Antibody 
Purification.
Determination of optimal elution conditions is essential for a successful 
affinity purification procedure. A binding buffer provides an environment favorable 
for the formation of the antibody-antigen complex, which is stabilized by noncovalent 
forces such as hydrophobic interactions, hydrogen bonds, van der Waals and 
Coulombic interactions, n-n interactions, etc. An elution buffer, in contrast, must 
sufficiently change the properties of the mobile phase to disrupt the antibody-antigen 
complex.146 147 In order to find the optimal elution buffer that can liberate the bound 
antibody in a minimum volume, ten different elution conditions were tested in 
noncompetitive ELISAs as described for the anti-D-AHA 73 and the anti-L-AHA 65 
antibodies in Chapter II, section Antibody Purification. The percent binding was 
calculated using the formula (Aeb/Aref) x 100, where Arefis the absorbance value for 
binding in the reference buffer PBS, and Aeb is the absorbance value after incubating 
with the respective elution buffer.146 For both antibodies, acidic and basic conditions 
generally resulted in a significant decrease in the amount of bound antibody. Water 
and 4 M sodium chloride did not significantly decrease the amount of bound antibody. 
TEA showed the largest decrease in the percentage of bound antibody. While 
100 mM TEA was more effective at eluting antibody, 10 mM TEA was chosen for 
elution to limit antibody denaturation. Figure 9 shows the ELISA results obtained 
with anti-D-AHA 73. Similar results were obtained with anti-L-AHA 65.
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Figure 9: The efficacy of potential elution solvents for affinity purification was 
determined by noncompetitive ELISA. After binding of the primary antibody, the 
microtiter plate was incubated with the elution solvents for 10 min at room 
temperature. The antibody which remained bound was detected with HRP-labeled 
secondary antibody. PBS was used as a reference buffer.
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After selection of the elution conditions, antibodies from the interstitial 
fluids and sera of both rabbits were further purified by affinity chromatography as 
described in Chapter II, section Antibody Purification. With each batch of antibody 
purified, the majority of antibody eluted from the column with the void volume and 
successive washings with PBS. Only a negligible amount of protein was removed by 
washing with 1 M sodium chloride. Specific antibody was eluted from the column 
with 10 mM TEA. For the purification shown in Figure 10, 130 mg of ammonium 
sulfate precipitated interstitial fluid containing anti-D-AHA 73 was applied to the 
column (bed volume: 15 ml) at a concentration of 8.7 mg/mL. Eleven mg of specific 
antibody were eluted from the column; both flow-through and eluted antibody were 
tested for activity in noncompetitive ELISAs (Figure 11). No apparent overloading of 
the column occurred as the flow-through contained no detectable specific antibody 
(not shown). The eluted antibody, on the other hand, still showed specific, 
stereoselective interaction indicating that the antibody retained activity after elution. 
The percentage of hapten-specific antibody was comparable to that observed in other 
studies148,149 and ranged from 8-10% for both anti-D-AHA 73 and anti-L-AHA 65 
from either interstitial fluid or serum.





Figure 10: Affinity purification of anti-D-AHA 73 on CL4B Sepharose derivatized 
with /7-azo-D-PLA-tyramine. One mL fractions were collected upon elution with 
10 mM TEA and were measured at 280 nm (solid bars). Approximately 100 mg of the 
130 mg of protein applied to the column did not bind to the column and were collected 
with the 13 mL of flow-through (open bar). Another 20 mg of protein were collected 
after washing with PBS (diagonally lined bar). Subsequent washing with PBS and 
1 M sodium chloride did not remove any significant amounts of protein (not shown).
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Figure 11: Noncompetitive ELISA results for anti-D-AHA 73 before ( # ,0 )  and 
after (♦,<>) affinity purification. The concentration of the purified antibody was 
adjusted to 1/10 of the concentration of antibody in the unpurified sample so that the 
concentration of specific antibody was the same in both samples. Filled and open 
symbols represent binding to />-azo-D-PLA-BSA and /?-azo-L-PLA-BSA coatings, 
respectively. Values obtained with the BSA coating were subtracted. Data points 
represent means of triplicate determinations. Error bars are obscured by symbols.
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Affinity-purified antibodies were characterized in competitive ELISAs using 
free AHAs as competitors as described in Chapter II, section Enzyme-Linked 
Immunosorbent Assays. In the earliest immunoassays, developed by Rosalyn Yalow 
and Solomon Berson, anti-insulin antibodies were shown to bind to insulin labeled 
with radioactive iodine. Unlabeled insulin could compete with and thereby decrease 
the binding of labeled insulin to the anti-insulin antibodies. Alternatively, antibodies 
were labeled with a radioactive isotope.150,151 ELISAs eliminate the need for 
radioactive substances and are now more commonly used than RIAs.152,153 Either the 
antibody or the antigen can be labeled with an enzyme such as horseradish peroxidase 
or alkaline phosphatase, each of which can convert a colorless substrate to a colored 
product. Commercially available enzyme-labeled secondary antibodies can also be 
used to detect the primary antibody. Protein antigens can be adsorbed directly onto 
the plastic surfaces of microtiter plates commonly used in ELISAs. Haptens, which 
may not adsorb directly onto microtiter plates, may be conjugated to a protein prior to 
application onto the plate. The protein, in this case, should not be the same protein 
used for immunization, so as to avoid binding of antibodies which recognize the 
carrier protein instead of the hapten. Addition of competitor can inhibit binding of the 
primary antibody to antigen-coated plates. In the case of a competitor that binds 
strongly to the antibody, only a small amount of competitor is needed to inhibit the
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binding of antibody; conversely, larger amounts of competitor are needed if the 
competitor only binds weakly to the antibody.
Here, various free underivatized AHAs were used as competitors. The relative 
binding affinities of these AHAs were determined as IC50 values. The IC50 value is 
the concentration of inhibitor that leads to a 50% decrease in the amount of antibody 
bound to the plate. Absorbance values are converted to percent inhibition using the 
equation, percent inhibition = [l-(A/Ao)] x 100, where A represents values in the 
presence of competitor (at a certain concentration), while Ao is the absorbance in the 
absence of competitor.
As stated above, the extent of inhibition is strongly affected by the strength of 
interaction between antibody and competitor. Typically, the strongest binding 
affinities of anti-hapten antibodies are obtained with molecules which resemble the 
hapten. Because here the hapten, />amino-D- or -L-PLA, was conjugated to the KLH 
carrier via diazotization, of all AHAs tested the /i-azo-D- and -L-PLA-tyramine 
conjugates showed the strongest binding to the anti-D-AHA 73 and anti-L-AHA 65, 
respectively. The relative affinities of both antibodies for the respective />azo-D- or 
-L-PLA-tyramine conjugates were found to be in the low micromolar range, p- 
Amino-PLA and PLA also bind with micromolar affinities as shown in Figure 12 and 
Figure 13, respectively. Aliphatic AHAs bound with weaker affinities, i.e., in the 
millimolar range. Lactic acid bound with the weakest affinity of all AHAs tested 
(Figure 14). Aliphatic AHAs with longer side chains bound more strongly than lactic 
acid. Despite their weak affinity, however, the aliphatic AHAs still were bound
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Figure 12: Competitive ELISAs performed with a) anti-D-AHA 73 and b) anti-L- 
AHA 65 using/j-amino-PLA as competitor. Open circles (O) represent the L- 
enantiomer and closed circles ( • )  represent the D-enantiomer. Error bars indicate 
standard deviations of triplicate determinations. Missing error bars are obscured by 
symbols.
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Figure 13: Competitive ELISAs performed with a) anti-D-AHA 73 and b) anti-L-AHA 
65 using PLA as competitor. Open circles (O) represent the L-enantiomer and closed 
circles ( • )  represent the D-enantiomer. Error bars indicate standard deviations of 
triplicate determinations. Missing error bars are obscured by symbols.
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Figure 14: Competitive ELISAs performed with a) anti-D-AHA 73 and b) anti-L-AHA 
65 using lactic acid as competitor. Open circles (O) represent the L-enantiomer and 
closed circles ( • )  represent the D-enantiomer. Error bars indicate standard deviations 
of triplicate determinations. Missing error bars are obscured by symbols.
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stereoselectively by the corresponding antibodies. IC50 values determined in 
competitive ELISAs with various AHAs ranging from aromatic AHAs to lactic acid 
are given in Table 4 for anti-D-AHA 73 and in Table 5 for anti-L-AHA 65.
While the nature of the side chain affects the binding affinity, the 
hydroxyl/carboxyl/hydrogen triad about the stereogenic center is essential for 
stereoselective binding of AHAs to either antibody. Only AHAs of the correct 
configuration bind to the antibodies. No inhibition was observed using the “wrong” 
enantiomer as competitor in the range of concentrations tested. Since p-hydroxy-PLA, 
2 -hydroxyoctanoic acid, and 2 -hydroxyisocaproic acid were only available as racemic 
mixtures, relative affinity values for these three AHAs were determined using the 
concentration of the correct enantiomer (i.e., half of the total AHA concentration).
The simplifying assumption was made that the “wrong” enantiomer does not interact 
with the antibody.
i f
The anti-AA antibodies described by Hofstetter and Hofstetter also bound 
stereoselectively to a wide range of free AAs in competitive ELISAs. The influence 
of the side chain on the relative affinities showed a similar trend to the one observed 
here with the anti-AHA antibodies. The smallest IC50 values were obtained for AAs 
such as tyrosine and p-amino-Phe, whose structures resemble the hapten. Larger IC50 
values were obtained for aliphatic AAs. Furthermore, aliphatic AAs with longer side 
chains, in general, had smaller IC50 values than those with shorter side chains.
While polycolonal antibodies were produced first because of the relatively 
short time until antibodies could be obtained and because fewer animals are typically
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Table 4: Relative affinities of anti-D-AHA 73 to various a-hydroxy acids as 
determined by competitive ELISA__________________________________
















4.7 pM ± 1.7




















H3C ^ C O O H
OH
22.6 pM ± 0.6
567.5 pM ± 7.8
964.5 pM ± 2.1
2.83 mM ± 0.04
4.0 mM ± 1.0
91.61 mM ± 0.02
Values represent means of three independent measurements. 50% inhibition was not reached with the 
opposite enantiomer using maximum concentrations as follows: a) 100 pM, b) 500 pM, c) 2 mM, d) 1 
mM, e) 50 mM, f) 15 mM, g) 1 M, h) not determined.
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Table 5: Relative affinities of anti-L-AHA 65 to various a-hydroxy acids 
as determined by competitive ELISA_____________________________



































34.0 pM ± 3.8
52.7 pM ± 5.2
69.2 pM ± 6.2
210 pM ± 4
237 pM ± 2
905 pM ± 3
1.07 mM ± 0.07
5.52 mM ± 0.12
12.5 mM ± 0.6
224.4 mM ± 5.7
Values represent means of three independent measurements. 50% inhibition was not reached with the 
opposite enantiomer using maximum concentrations as follows: a) 2 mM, b) 5 mM, c) 50 mM, d) 200 
mM, e) 4 M, f) not determined.
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needed to obtain positive results, monoclonal antibodies are ultimately more useful. 
Monoclonal antibodies are homogeneous and have a uniform binding specificity. 
Monoclonal antibodies can theoretically be produced indefinitely once a cell line is 
established, but continued production of polyclonal antibodies is dependent on an 
animal’s survival. Additionally, monoclonal antibodies and their fragments can be 
used for structural analysis in X-crystallography. cDNA can also be obtained from 
monoclonal antibody-producing hybridomas for sequence determination.
Production and Characterization of Monoclonal Antibodies 
Immune Responses and Selection of Mice
The production of monoclonal antibodies hinges on the fact that only one 
particular antibody molecule is produced by a given B-lymphocyte. Individual B- 
lymphocytes were shown to produce antibodies as early as 1958 by Nossal and 
Lederberg.154 In 1963, Jeme and Nordin had developed the agar-gel plaque technique 
for visualizing single antibody-producing cells.155 By 1967, Makela demonstrated that 
the antibodies produced from such single immunocytes showed remarkable specificity 
for a single ligand.156 In the same year, Green et al. used immunofluorescent 
techniques to prove that cells producing anti-hapten antibodies did not produce anti­
carrier antibodies, and, likewise, the cells which produced antibodies against the 
carrier did not produce any anti-hapten antibodies.157 Klinman, in 1969, confirmed
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quantitatively that clones from a single B-lymphocyte produce homogeneous 
antibodies.158 Because many B-lymphocytes respond when an animal is injected with 
an immunogen, multiple clonotypes are produced to yield a “polyclonal antibody.” 
Klinman, in his subsequent experiments, estimated that a BALB/c mouse containing 
about 2 x 108 B-cells can, theoretically, generate 1-4 x 107 distinct clonotypes.159 
Theoretically, several different clonotypes could be produced for a given epitope, as 
one out of every 10,000 clonotypes may potentially produce antibody against a given 
epitope.159 160 However, only few distinct antibodies are produced since only a few B- 
cell clones are activated.52,161'163
In “multiple myeloma,” cancerous tumors of B-lymphocytes secrete 
monoclonal antibodies. While these antibody-secreting tumors had been known for 
years, the binding activity of such antibodies was unknown before 1967.164 In fact, 
many researchers believed that they could not bind antigen.164 Eisen et al., however, 
finally demonstrated that antibodies secreted from myeloma tumors could bind to an 
antigen, specifically DNP-lysine.165 Since that time, more antibodies from myeloma 
tumors have been shown to bind to antigens.166'169 In addition to naturally occurring 
myelomas, Michael Potter and C. R. Boyce found that myelomas can be induced in 
mice by intraperitoneal injections of mineral oil.170,171 While cells from both 
naturally occurring and induced myelomas can be grown in cell culture, isolation of 
such myeloma cells producing antibodies with desired binding characteristics is
1 79impractical. B-cells from an immunized animal secrete antibodies of known 
antigenic activity, yet they can only be maintained in tissue culture for a short time.
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The hybridoma technology, pioneered by Kohler and Milstein, made it 
practical not only to isolate B-cells, which secrete monoclonal antibodies with known 
specificity, but also to grow those cells in culture.53,54 Theoretically, unlimited 
quantities of homogeneous antibodies may be produced continuously from one cell 
line. Briefly, the animal, typically a mouse or rat, is first inoculated in order to 
stimulate B-lymphocytes that recognize the antigen; these cells will become antibody- 
producing plasma cells. Following subsequent booster injections, serum from test 
bleeds containing polyclonal antibodies is screened for antibodies with the desired 
binding properties. An animal with a good immune response is boosted with the 
immunogen just a few days prior to fusion. B-cells harvested from lymphoid tissues 
are then fused in vitro with an immortal, nonantibody-producing myeloma cell.
Sendaii virus was originally used by Kohler and Milstein to fuse splenocytes and 
myelomas.53,173 Since that time, polyethylene glycol (PEG) and electrofusion have 
both been used to fuse cells; however, today PEG is the most commonly used fusing
1 7 4  1 77agent. ' As hybridomas are present only in small amounts in a cell mixture, which 
also includes unfused myeloma and B-lymphocytes, lymphocyte-lymphocyte, and 
myeloma-myeloma fused cells, the cells are grown in a selective medium containing 
HAT, in which only hybridoma cells survive. Detailed descriptions of the processes 
and methods involved in the production of monoclonal antibodies are given in Chapter 
I and Chapter II, section Antibody Production.
Initially, production of monoclonal antibodies by classical immunological 
methods requires essentially the same steps as the production of polyclonal antibodies.
R ep ro d u ced  with p erm issio n  o f  th e  copyrigh t ow n er. Further reproduction  prohibited w ithout p erm ission .
80
Because immune responses may vary among animals, multiple mice or rats are 
typically inoculated. Polyclonal antibodies are typically obtained from immunized 
animals to select the animal with the optimal immune response for use in hybridoma 
production. Using multiple animals also provides an opportunity for repeated cell 
fusions should the first attempt be unsuccessful.
Because the goal of this part of the dissertation was to produce and 
characterize stereoselective monoclonal antibodies against AHAs, five mice were 
inoculated intraperitoneally with /?-azo-D-PLA-KLH in CFA as described in Chapter 
II, section Antibody Production. Another five mice were inoculated with p-azo-L- 
PLA-KLH in CFA. Booster injections of the respective immunogen in IFA were 
given two weeks later. Four weeks after the first inoculation, each mouse was given a 
second booster injection of the respective immunogen in PBS. Serum samples were 
collected from the tail of each mouse one month after the second booster injection. 
These samples were tested for specific stereoselective antibody in noncompetitive 
ELISAs as described in Chapter II, section Enzyme-Linked Immunosorbent Assay. 
Sample binding curves are presented in Figure 15 a) for samples from mouse #1 and 
mouse #2, which were inoculated with/>-azo-D-PLA-KLH. Figure 15 b) shows 
sample binding curves for mouse #6 and mouse #60 inoculated with p-azo-L-PLA- 
KLH. The titers determined for serum samples of all mice were in the range between 
1/10,000 and 1/100,000.
Typically, high serum titers are considered indicative of a good immune 
response. High titers, however, do not guarantee the presence of an antibody of high
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Figure 15: Noncompetitive ELISA results for polyclonal antibody-containing sera 
from mice inoculated with a) />azo-D-PLA-KLH and b) p-azo-L-PLA-KLH. In graph 
a), mice #1 and #2 are represented by ( # ,0 )  and (♦,<>), respectively. In graph b), 
mice #6 and #60 are represented by ( # ,0 )  and (♦,<>), respectively. p-Azo-D-PLA- 
BSA (closed symbols), p-azo-L-PLA-BSA (open symbols), and BSA were used as 
solid-phase coatings. At each dilution, the values obtained with the BSA coating were 
subtracted from those obtained on the other two coatings.
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affinity as the titer may be based on a high level of antibody production. The 
affinity of the antibody should, therefore, be tested in, e.g., a competitive ELISA. 
Mouse #1 had good titers and exhibited the most stereoselective immune response of 
all mice inoculated with p-azo-D-PLA-KLH. Of the mice inoculated with p-azo-L- 
PLA-KLH, mouse #60 exhibited the most stereoselective immune response and also 
had a good titer. Therefore, the polyclonal antibody-containing sera from these two 
mice were further tested in competitive ELISAs (Figure 16). An IC50 value of 15 pM 
was obtained for the binding of the polyclonal antibody from mouse #1 to D-PLA. For 
the serum sample from mouse #60, an IC50 value of 112 pM was obtained for the 
binding of the polyclonal antibody to L-PLA. As with the polyclonal rabbit 
antibodies, no inhibition was observed using the “wrong” enantiomer as competitor in 
the range of concentrations tested. The spleens from mice #1 and #60 were harvested 
for fusion to produce hybridoma cells because both mice had good stereoselective 
immune responses.
Production and Selection of Hvbridomas
Mouse #1 and mouse #60 were given booster injections ofp-azo-D-PLA-KLH 
and p-azo-L-PLA-KLH, respectively, in PBS three to four days prior to harvesting 
their spleens as described in Chapter II, section Antibody Production. Splenocytes 
from each mouse were fused separately with P3x63AG8 myeloma cells. Within an 
hour after fusion, formation of fused cells could be observed upon microscopic
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Figure 16: Competitive ELIS As of polyclonal antibody-containing sera from a) mouse 
#1, which was inoculated with /?-azo-D-PLA-KLH, and b) mouse #60, which was 
inoculated with p-azo-L-PLA-KLH using PLA as competitor. Open circles (O) 
represent the L-enantiomer and closed circles ( • )  represent the D-enantiomer. Error 
bars indicate standard deviations of triplicate determinations. Missing error bars are 
obscured by symbols.
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examination (Figure 17a). After being exposed to the HAT selective medium, 
multiple clumps of growing hybridoma cells could be seen after about one week 
(Figure 17b). Two weeks after fusion, the medium in some of the wells began to 
change color, indicating a pH change due to by-products of cellular metabolism, 
typically lactic acid. The supernatant was collected from the wells when the medium 
changed color. The samples were then tested in noncompetitive ELISAs as described 
in Chapter II, section Enzyme-Linked Immunosorbent Assay. Within a month, the 
bottoms of most of the wells were covered with a layer of cells (Figure 17c). By two 
months, the supernatant from most wells had been tested for specific antibody. 
Supernatant from any wells not previously tested were tested at this time and the 
culture plates were discarded to prevent infection.
Of the hybridomas produced from the splenocytes of the mouse inoculated 
with p-azo-D-PLA-KLH, eight produced antibodies that exhibited strong 
stereoselective binding to the p-azo-D-PLA-BSA coating; no significant 
binding to p-azo-L-PLA-BSA or BSA coatings was observed in noncompetitive 
ELISA ( Figure 18). One clone, 0D11, secreted antibodies exhibiting significant 
cross-reactivity to the p-azo-L-PLA-BSA coating.
Nine hybridomas of those produced from the splenocytes of the mouse 
inoculated with p-azo-L-PLA-KLH produced antibodies that bound strongly to the p- 
azo-L-PLA-BSA coating (Figure 19). One of these antibodies, anti-L-AHA 5F12, also 
exhibited strong binding to the p-azo-D-PLA-BSA coating. None of these nine 
antibodies showed significant binding to the BSA coating.
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Figure 17: Hybridomas are grown in cell culture after they are produced by fusing 
lymphocytes and myeloma cells, a) Cells begin to fuse within an hour of treatment 
with polyethylene glycol (400 x magnification), b) Clumps of growing cells can be 
seen in about one week (200 x magnification); however, cell debris from dying cells is 
also seen, c) Cells cover the bottoms of many of the wells one month after fusion (200 
x magnification).




2B11 3G11 4G3 4G4 5E9 8E10 9C8 10B2 0D11
anti-D-AHA producing hybridoma clone
Figure 18: Cell culture supernatants were screened for antibodies that bind top-azo- 
D-PLA-BSA coating (solid bars) in noncompetitive ELISA. The antibody-producing 
hybridomas were produced by fusing splenocytes from mouse #1, which was 
inoculated with p-azo-D-PLA-KLH. Cell culture supernatants were also screened 
against />azo-L-PLA-BSA (horizontally lined bars) and BSA (open bars) coatings.











3E11 3G5 3H5 5H9 5C9 6C1 3B2 5F12 6A3
anti-L-AHA producing hybridoma clone
Figure 19: Cell culture supernatants were screened for antibodies that bind to p-azo-L- 
PLA-BSA coating (horizontally lined bars) in noncompetitive ELISA. The antibody- 
producing hybridomas were produced by fusing splenocytes from mouse #60, which 
was inoculated with p-azo-L-PLA-KLH. Cell culture supernatant was also screened 
against p-azo-D-PLA-BSA (solid bars) and BSA (open bars) coatings.
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Characterization of Monoclonal Antibodies
While noncompetitive ELISAs represent an efficient method for initial 
screening of antibody-producing clones, competitive ELISAs are more useful to 
determine affinities of secreted antibodies. The aforementioned eighteen monoclonal 
antibodies were further characterized by competitive ELISAs as described in Chapter 
II, section Enzyme-Linked Immunosorbent Assay, using PLA as inhibitor. IC50 values 
were determined from competitive ELISAs using both D-and L-PLA as inhibitors. All 
IC50 values, determined with the “correct” enantiomer, were in the micromolar range 
between 5 pM and 551 pM (Table 6). The “wrong” enantiomer, in the range of 
concentrations tested, did not bind to any of the antibodies except anti-D-AHA 0D11 
and anti-L-AHA 5F12. These two antibodies, which bound to both p-azo-D- and -L- 
PLA-BSA coatings in noncompetitive ELISAs, were inhibited by both D- and L-PLA 
in competitive ELISA (Figure 20), which provided further confirmation of their cross­
reactivity. IC50 values for anti-D-AHA 0D11 were 279 pM and 425 pM for D-PLA 
and L-PLA, respectively (Figure 20a). The IC50 value for anti-L-AHA 5F12 was 353 
pM for both enantiomers of PLA (Figure 20b).
In most vertebrates, there are five distinct classes of immunoglobulins that 
differ from each other in size, overall charge, amino acid composition, carbohydrate 
content, and immunological function. The five immunoglobulin classes are
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Table 6: Relative affinities of various monoclonal antibodies to phenyllactic acid 
as determined by competitive ELISA
Antibody IC50 Antibody Om
uHH
anti-D-AHA 2B11 175 pM anti-L-AHA 3G5 551 pM
anti-D-AHA 3G11 169 pM anti-L-AHA 3E11 220 pM
Anti-D-AHA 4G3 24 pM anti-L-AHA 3H5 282 pM
Anti-D-AHA 4G4 189 pM anti-L-AHA 6A3 154 pM
Anti-D-AHA 5E9 62 pM anti-L-AHA 3B2 130 pM
anti-D-AHA 8E10 5.3 pM anti-L-AHA 5H9 482 pM
Anti-D-AHA 9C8 145 pM anti-L-AHA 6C1 529 pM
anti-D-AHA 10B2 40 pM anti-L-AHA 5C9 298 pM
IC50 values were determined using the concentration of the “correct” enantiomer, i.e., 
D-PLA for anti-D-AHA antibodies and L-PLA for anti-L-AHA antibodies.
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Figure 20: Competitive ELISAs using phenyllactic acid as competitor obtained with a) 
anti-D-AHA OD11 and b) anti-L-AHA 5F12. Open circles (O) represent the L- 
enantiomer and closed circles ( • )  represent the D-enantiomer. Error bars indicate 
standard deviations of triplicate determinations. Missing error bars are obscured by 
symbols.
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designated IgM, IgG, IgA, IgD, and IgE. Primarily, each class is distinguished by 
unique amino acid sequences in the heavy chain constant region that confers class- 
specific structural and functional properties. These different classes can be isolated 
from serum using a combination of fractional precipitation and ion-exchange or size- 
exclusion chromatography.178 Partial purification of antibodies from serum can be 
achieved by electrophoresis, which results in three fractions of globulins, designated 
a, (3, and y, and one fraction containing albumin.179 Tiselius and Kabat determined 
that the y-globulin fraction of serum contained antibodies (i.e., immunoglobulins) by 
raising antibodies against ovalbumin and analyzing serum using electrophoresis.179 
One aliquot of serum was reacted with ovalbumin and the precipitate containing 
antibody was removed. Another aliquot of serum was not reacted with antigen. 
Comparison of the two fractions revealed that the aliquot that had been reacted with 
antigen was significantly depleted in the y-globulin fraction. It is now known that IgG 
antibodies are mostly found in the y-globulin fraction while other classes of antibodies 
are found in the a  and P fractions of serum.180 IgG is the most abundant 
immunoglobulin in serum, accounting for 70-75% of the total immunoglobulin 
concentration. In mouse, there are four IgG subclasses, IgGl, IgG2a, IgG2b, and 
IgG3, which have dissimilar heavy chain amino acid sequences. In fact, some
researchers consider these four IgG subclasses different classes, called IgF, IgG, IgH,
181 • • and Igl. The immunoglobulin classes and subclasses are encoded by different
genes. The unique heavy chains of each class and subclass can be identified using
anti-isotype antibodies, which are produced by inoculating an animal of one species
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• * 1 8 2with an antibody of a particular class or subclass from a different species.
Isotype determination is important, e.g., for production of cDNA and sequence 
determination and certain purification methods. Therefore, the isotypes of the nine 
anti-D-AHA and nine anti-L-AHA antibodies were determined as described in Chapter 
II, section Isotype Determination. All antibodies were found to be of the IgG class 
(Table 7). Specifically, anti-D-AHA 0D11, anti-L-AHA 5C9, and anti-L-AHA 5F12 
are IgG2b. However, the other fifteen antibodies are IgGl.
Purification of Monoclonal Antibodies
Two antibodies, anti-D-AHA 8E10 and anti-L-AHA 6A3, were purified for 
further characterization by ammonium sulfate precipitation, Melon™ Gel purification, 
and affinity purification as described in Chapter II, section Antibody Purification. 
Because antibodies are found in cell culture supernatant in relatively low 
concentrations, precipitation of antibody directly from cell culture supernatant may be 
unproductive. A higher fraction of antibody may be recovered if cell culture 
supernatant is first concentrated. Cell culture supernatants containing anti-D-AHA 
8E10 and anti-L-AHA 6A3 were each concentrated as described in Chapter II, section 
Antibody Purification. Typically, 100 mL batches of cell culture supernatant were 
concentrated to 10 mL. Because the horse serum used in cell culture medium contains 
significant amounts of protein, the supernatant became increasingly viscous in the
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Table 7: Isotypes of various monoclonal antibodies
Antibody Isotype Antibody Isotype
anti-D-AHA 2B11 IgGl anti-L-AHA 3G5 IgGl
anti-D-AHA 3G11 IgGl anti-L-AHA 3E11 IgGl
anti-D-AHA 4G3 IgGl anti-L-AHA 3H5 IgGl
anti-D-AHA 4G4 IgGl anti-L-AHA 6A3 IgGl
anti-D-AHA 5E9 IgGl anti-L-AHA 3B2 IgGl
anti-D-AHA 8E10 IgGl anti-L-AHA 5H9 IgGl
anti-D-AHA 9C8 IgGl anti-L-AHA 6C1 IgGl
anti-D-AHA 10B2 IgGl anti-L-AHA 5C9 IgG2b
anti-D-AHA 0D11 IgG2b anti-L-AHA 5F12 IgG2b
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concentration process, making it impractical to concentrate supernatants by more 
than a factor of ten.
The antibody was precipitated from the concentrated cell culture supernatant 
using 50% saturated ammonium sulfate solution as described in Chapter II, section 
Antibody Purification. The proteins from horse serum including albumin and horse 
antibody coprecipitated with the murine antibodies (Figure 21). The antibodies were 
then further purified by Melon™ Gel in order to remove protein impurities like 
albumin and transferrin (Figure 22). While the manufacturer’s instructions only 
describe purification of antibodies from serum, antibodies from cell culture 
supernatant could also be purified here using the same procedure once precipitated 
antibody was dissolved in PBS at concentrations between 15 and 20 mg/mL. After 
Melon™ Gel purification, the antibodies were concentrated to 5 mg/mL. Melon™
Gel purification, however, could not remove unwanted horse antibody. The anti-D- 
AHA 8E10 and the anti-L-AHA 6A3 were therefore isolated by affinity purification 
using the same />azo-D- and -L-PLA-tyramine Sepharose, respectively, that was used 
for the affinity purification of the polyclonal rabbit antibodies. Possible elution 
buffers were tested in noncompetitive ELISA as described in Chapter II, section 
Antibody Purification. TEA was found to effectively prevent binding of both anti-D- 
AHA 8E10 and anti-L-AHA 6A3 to their respective antigens on the plate. Even if 100 
mM TEA was more effective at eluting antibody, 10 mM TEA was chosen to prevent 
antibody denaturation. Binding, washing and elution steps using the
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Figure 21: Nonreducing sodium dodecyl sulfate-polyacrylamide gel electrophoresis of 
concentrated cell culture supernatant containing anti-L-AHA 6A3 (lane 1).
Supernatant was precipitated with 50% saturated ammonium sulfate. The precipitate 
still contained albumin in addition to both horse and murine antibodies (lane 3). The 
majority of protein in cell culture supernatant comes from horse serum (lane 2). Lane 
5 contains the MW marker and lane 4 is a positive control.
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Figure 22: Nonreducing sodium dodecyl sulfate-polyacrylamide gel electrophoresis of 
anti-L-AHA 6A3 purified from cell culture supernatant by Melon M Gel (lane 2). 
Melon™ Gel purification removed protein contaminates (e.g., albumin) that remained 
after precipitation with 50% saturated ammonium sulfate (lane 1). Such
T X  A  T X  Acontaminating proteins bind to the Melon Gel resin and are eluted with the Melon 
Gel regeneration buffer (lane 3). Lane 5 contains the MW marker and lane 4 is a 
positive control.
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monoclonal antibodies were analogous to the purification of polyclonal rabbit 
antibodies.
Following ammonium sulfate precipitation and Melon™ Gel purification,
80 mg of the antibody sample containing anti-D-AHA 8E10 at 5 mg/mL were applied 
to the column (bed volume: 15 mL) for the purification shown in Figure 23. Seven mg 
of specific antibody were eluted from the column. Similar to the polyclonal rabbit 
antibodies, the eluted antibody showed specific, stereoselective interaction indicating 
that the antibody retained activity after elution as determined by noncompetitive 
ELISA (not shown). The flow-through, however, contained no detectable specific 
antibody. Purification of anti-L-AHA 6A3 gave similar results following the same 
purification procedures. Six mg of specific anti-L-AHA 6A3 were obtained from 
80 mg of precipitated Melon™ Gel purified cell-culture supernatant antibody. The 
concentration of hapten-specific antibody in cell-culture supernatant thus ranged from 
60-70 pg/ml for both anti-D-AHA 8E10 and anti-L-AHA 6A3. Values are 
comparable to that observed in other studies.183,184
Competitive ELISAs
Anti-D-AHA 8E10 and anti-L-AHA 6A3 were further tested for their ability to 
bind to various free AHAs. Competitive ELISAs were performed as described in 
Chapter II, section Enzyme-Linked Immunosorbent Assay. The concentration of free 
AHAs required to inhibit antibody binding by 50% (IC50 value) was used to evaluate
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Figure 23: Affinity purification of anti-D-AHA 8E10 on CL4B Sepharose derivatized 
with/7-azo-D-PLA-tyramine. One mL fractions were collected upon elution with 
10 mM TEA and measured at 280 nm (solid bars). Approximately 60 mg of the 80 
mg of protein applied did not bind to the column and were collected with the 20 mL 
flow-through (open bars). Another 13 mg of protein were collected after washing with 
PBS (diagonally lined bars). Subsequent washing with PBS and 1 M sodium chloride 
did not remove any significant amounts of protein (bars obscured).
R ep ro d u ced  with p erm issio n  o f  th e  copyrigh t ow n er. Further reproduction  prohibited w ithout p erm ission .
99
the relative binding affinities for these compounds. As observed with the 
polyclonal antibodies, the strongest binding affinities were obtained with AHAs that 
resemble the hapten, such as p-amino-D- or -L-PLA; weaker binding affinities were 
obtained with aliphatic AHAs. Specifically, the p-azo-PLA-tyramine conjugates 
showed the strongest binding and lactic acid the weakest binding of all AHAs tested. 
The relative affinities of both antibodies for the respective jo-azo-D- or -L-PLA 
tyramine conjugates were in the micromolar range while the relative affinities for the 
respective D- or L-lactic acid were in the millimolar range. Sample inhibition curves 
are given in Figure 24 for PLA and in Figure 25 for lactic acid. IC50 values of various 
AHAs determined in competitive ELISAs ranging from aromatic AHAs to lactic acid 
are given in Table 8 for anti-D-AHA 8E10 and in Table 9 for anti-L-AHA 6A3.
As previously described, the immunogen was designed to produce antibodies 
that recognize the hydrogen/carboxyl/hydroxyl triad about the alpha carbon of AHAs 
but are cross-reactive with regard to the side chain. The ELISA results confirmed that 
these antibodies in fact recognize a wide range of AHAs, including aliphatic AHAs, 
which differ significantly in their side chain structure from the hapten. As expected, 
aliphatic AHAs did bind more weakly than AHAs resembling the hapten. These 
results are in agreement with the results obtained with the polyclonal anti-D-AHA 73, 
anti-L-AHA 65, and the analogous anti-AA antibodies described by Hofstetter et al., 
which bind more strongly to amino acids resembling the hapten.59,60
The ability of both anti-AHA and previously produced anti-AA antibodies to 
bind various AHAs and AAs, respectively, is likely due to so-called “true cross-
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Figure 24: Competitive ELISAs performed with a) anti-D-AHA 8E10 and b) anti-L- 
AHA 6A3 using PLA as competitor. Open circles (O) represent the L-enantiomer and 
closed circles ( • )  represent the D-enantiomer. Error bars indicate standard deviations 
of triplicate determinations. Missing error bars are obscured by symbols.
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Figure 25: Competitive ELISAs performed with a) anti-D-AHA 8E10 and b) anti-L- 
AHA 6A3 using lactic acid as competitor. Open circles (O) represent the L- 
enantiomer and closed circles ( • )  represent the D-enantiomer. Error bars indicate 
standard deviations of triplicate determinations. Missing error bars are obscured by 
symbols.
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Table 8: Relative affinities of anti-D-AHA 8E10 to various a-hydroxy acids 
as determined by competitive ELISA________________________________
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h3c ^ c o o h  
_QH_
0.20 pM ± 0.03
0.98 pM ± 0.31 
2.7 pM ± 0.6 
5.3 pM ± 0.8 
9.2 pM ± 1.3
686.0 pM ±1.2
747.1 pM ± 2.8
950 pM ± 1
1.21 mM ± 0.02 
23.3 mM ± 0.8
Values represent means of three independent measurements. 50% inhibition was not reached with the 
opposite enantiomer using maximum concentrations as follows: a) 25 pM, b) 50 pM, c) 5 mM, d) 10 
mM, e) 15 mM, f) 50 mM, g) 1 M, h) not determined.
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Table 9: Relative affinities of anti-L-AHA 6A3 to various a-hydroxy acids as 
determined by competitive ELISA____________________________________





























35.6 pM ± 0.1
36.2 pM ± 1.4
*^COOH
OH 42.2 pM ±1.6
154.3 pM ±1.2
i H 158.5 ± 2.1
,COOH
1.4 mM ± 0.1
5.1 mM ±0.1
5.6 mM ± 0.2
15.3 mM ± 0.3
220.2 mM ± 0.4
Values represent means of three independent measurements. 50% inhibition was not reached with the 
opposite enantiomer using maximum concentrations as follows: a) 1 mM, b) 5 mM, c) 10 mM, d) 50 
mM, e) 500 mM, f) 4M, g) not determined.
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reactivity.” As explained first by Berzofsky and Schechter185 and later by van 
Regenmortel,186 “true cross-reactivity” arises when the same antibody is able to 
recognize different compounds that are structurally related to the hapten. Typically, 
the antibody will bind more strongly to the hapten used for producing the antibody and 
structures resembling this hapten. The similarity of binding exhibited by polyclonal 
antibodies and monoclonal antibodies, furthermore, suggests that the ability of 
polyclonal antibodies to bind to a large variety of compounds is also based on “true 
cross-reactivity.”
The “correct” configuration of the hydrogen/carboxyl/hydroxyl triad was also 
essential for binding of both anti-D-AHA 8E10 and anti-L-AHA 6 A3. D-AHAs did 
not inhibit the binding of anti-L-AHA 6A3 to the solid-phase immobilized antigen, nor 
did L-AHAs inhibit anti-D-AHA 8E10 in the range of concentrations tested. As 
described in Chapter III, section Production and Characterization of Polyclonal 
Antibodies, the correct three-dimensional arrangement of the hydrogen/carboxyl/ 
hydroxyl triad is equally important for the binding of anti-D-AHA 73 and anti-L-AHA 
65 antibodies. Similar observations were made by Hofstetter et al. for the binding of 
anti-AA antibodies, where the “correct” configuration of the hydrogen/carboxylate/ 
primary amino triad is essential.
In order to further investigate the specificity of anti-AHA antibodies, their 
interaction with structurally closely related molecules was examined next. This study 
included also a comparison with the anti-AA antibodies produced by Hofstetter et 
al.59’60
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Comparison of Anti-AA and Anti-AHA Antibodies
AAs and AHAs are structurally related classes of compounds which, as their 
names indicate, have an amino group or a hydroxyl group, respectively, attached to the 
alpha carbon. At physiological pH, AAs are zwitter ions comprising a positively 
charged amino and a negatively charged carboxyl group. Because the hydroxyl group 
of AHAs is uncharged, AHAs with uncharged side chains have an overall negative 
charge at physiological pH, which is due to the deprotonated carboxylate group.
While the polar hydroxyl group of AHAs can be either a hydrogen bond donor or a 
hydrogen bond acceptor, the amino group of AAs will act as hydrogen donor at 
physiological pH. However, reliable prediction of the specificity or cross-reactivity of 
antibodies raised against AAs and AHAs, respectively, merely based on the structural 
similarity or specific differences between these compounds, is not possible.
Therefore, both noncompetitive and competitive ELISAs were performed to compare 
the class-specificity of anti-AA and anti-AHA antibodies. Furthermore, competitive 
ELISAs were performed to evaluate the effect of replacing the carboxyl or hydroxyl 
groups on the a-carbon using closely related molecules as competitors.
First, anti-AHA antibodies were tested for binding to p-azo-D- and -L-Phe- 
BSA coatings, respectively, as compared to their binding to p-azo-D- and -L-PLA- 
BSA coatings. No significant binding was detected on either “amino acid coating.”
As previously observed, the anti-AHA antibodies bound only to the “correct”
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enantiomer of the p-azo-PLA-BSA coating. Figure 26a shows a sample binding 
curve for anti-L-AHA 65. Comparable results were obtained with anti-D-AHA 73, 
anti-L-AHA 6A3, and anti-D-AHA 8E10 antibodies. The anti-D-AA 67.36 and anti-L- 
AA 29.2 antibodies were tested likewise for binding to both the /?-azo-D- and -L-Phe 
BSA coatings and the p-azo-D- and -L-PLA-BSA coatings. Also here, the antibody 
only bound to the correct antigen coating with regard to both the correct class and 
configuration. Thus, anti-D-AA 67.36 bound only to /?-azo-D-Phe-BSA coating 
(Figure 26b), whereas anti-L-AA 29.2 bound only to the />-azo-L-Phe-BSA coating 
(not shown).
Competitive ELISAs using free AAs and AHAs as competitors were 
performed to confirm the class-specificity of these antibodies. Anti-D-AHA 73, anti- 
L-AHA 65, anti-D-AHA 8E10, anti-L-AHA 6A3, anti-D-AA 67.36, and anti-L-AA
29.2 were each tested in competitive ELISAs using four inhibitors: D- and L-Phe and 
D- and L-PLA. Each antibody only bound to the competitor of the correct 
configuration and class. No detectable interaction was seen with any of the other three 
competitors in the range of concentrations tested. For example, binding of the anti-D- 
AHA 73 was only inhibited by D-PLA and not by L-Phe, L-PLA, or D-Phe; anti-D-AA
67.36 was only inhibited by D-Phe and not by L-Phe, L-PLA, or D-PLA (Figure 27).
Both noncompetitive and competitive ELISAs confirmed the class-specificity 
and stereoselectivity of the six antibodies investigated in this study. The anti-D-AHA 
8E10 and anti-L-AHA 6A3 antibodies were further investigated to test the importance 
of functional groups about the stereogenic center, i.e., the hydrogen/carboxyl/hydroxyl
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Figure 26: Noncompetitive ELISA results obtained with a) anti-L-AHA 65 and b) anti- 
D-AA 67.36. /?-Azo-d-PLA-BSA ( • ) ,  /?-azo-L-PLA-BSA (O), p-azo-D-Phe-BSA 
(■), p-azo-L-Phe-BSA (□ ), and BSA were used as solid-phase coatings. At each 
dilution, the values obtained with the BSA coating were subtracted from those 
obtained on the other two coatings. Data points represent means of triplicate 
determinations. Error bars are obscured by symbols.
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Figure 27: Competitive ELIS As performed with a) anti-D-AHA 73 and b) anti-D-AA
67.36 using PLA and Phe as inhibitors. Open circles (O) represent L-PLA, closed 
circles ( • )  represent D-PLA, open squares (□ ) represent L-Phe, and closed squares 
(■ ) represent D-Phe. Error bars indicate standard deviations of triplicate 
determinations. Missing error bars are obscured by symbols.
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triad, for binding. Phenylpropionic acid and phenyllactic acid methyl ester were 
each used as competitors in further competitive ELISAs. While phenylpropionic acid, 
the dehydroxylated analog of PLA, is achiral, phenyllactic acid methyl ester, in which 
the carboxyl group of PLA is substituted by a methyl ester, is chiral. Both 
phenylpropionic acid and phenyllactic acid methyl ester lack the hydrogen/carboxyl/ 
hydroxyl triad of AHAs. Neither compound inhibited the binding of anti-D-AHA 
8E10 to the p-azo-D-PLA-BSA coating or of anti-L-AHA 6A3 to the /?-azo-L-PLA- 
BSA coating (Figure 28).
Historically, medicinal chemists have believed that the structural similarity of 
molecules would correlate with similar biological activities. Replacement of atoms or 
groups of atoms with closely related atoms or groups, therefore, has widely been used 
to modify the biological activity of potential enzyme inhibitors, receptor agonists, 
antagonists, and other biologically active molecules. Such “bioisosteric replacement” 
can indeed be an effective route to optimize so-called lead structures into 
therapeutically useful drugs and therapies.187 Several parameters must be considered 
in the selection and modification of molecules.187 In order to attain the needed 
biological activity, a given ligand must fit in the binding site of the corresponding 
biological macromolecule. The hydrophobic or polar surface areas within the binding 
site should likewise match. While exchange of one hydrogen bond donor for another, 
or of one hydrogen bond acceptor for another, may not significantly affect activity, 
exchange of a hydrogen bond donor for an acceptor or vice versa will most likely 
affect binding by several orders of magnitude. Although such considerations may
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Figure 28: Competitive ELIS As performed with a) anti-D-AHA 8E10 and b) anti-L- 
AHA 6A3 using L-PLA (O), D-PLA ( • ) ,  phenylpropionic acid (♦ ) ,  and phenyllactic 
acid methyl ester (O ) as inhibitors. D-Phenyllactic acid methyl ester was used in a) 
and the L-enantiomer was used in b). Error bars indicate standard deviations of 
triplicate determinations. Missing error bars are obscured by symbols.
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provide reasonable guidelines for bioisosteric replacements, several structure- 
function relationship studies showed that chemically similar molecules can have
1 88 1 onsignificantly different biological activities. ' Hence, bioisosteric replacement of 
atoms or groups may result in decreased, increased, or unchanged biological 
activity.187’190
Arrhenius first described the binding of antibodies in chemical terms using 
mathematical descriptions from physical chemistry in the early 1900s.191 However, 
chemical descriptions of antibody-antigen binding were limited because little was 
known about the structure of antigens. Landsteiner circumvented this problem by 
using anti-hapten antibodies to systematically study the effect of both an antigen’s 
structure and its specific functional groups on antibody binding. Landsteiner studied 
the binding of anti-hapten antibodies to both the hapten and other closely related 
molecules using immunoprecipitation reactions.51 Hapten analogs with modified 
stereochemistry and/or functional groups were used, first by Landsteiner and later by 
others, to identify structural features important for the binding of such antibodies. For 
example, one study by Pressman and Siegel of an anti-/>(/f -azophenylazo)- 
benzenearsonate antibody showed little difference between binding to p-(p'- 
aminophenylazo)-benzenearsonate and to /?-(p’-hydroxyphenylazo)- 
benzenearsonate.192 /?-Amino-benzenearsonate and p-hvdroxy-benzenearsonate both 
bound more weakly to the same anti-p-(/?’-azophenylazo)-benzenearsonate antibody 
but with nearly the same binding affinity as each other.192 No other studies comparing 
the effect of amino and hydroxyl functional groups of haptens on the binding of anti-
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hapten antibodies have been found by the author. However, it should be noted that 
the amino and hydroxyl groups in Pressman and Siegel’s studies were unlikely to 
interact in any significant way directly with antibody, as they were positioned away 
from the antibody binding site. The effect of substituting an amino group for a 
hydroxyl group or vice versa in inhibitors, antibiotics, and other ligands on their 
biological activity, though, has been investigated in a number of studies.
Functional groups in antibiotics are frequently modified in order to optimize 
their selectivity and to combat antibiotic resistance. Several aminoglycoside 
antibiotics have been studied, in which one or more hydroxyl groups were converted 
to an amine. Both the location and number of amino groups were found to possibly 
affect antibiotic activity in prokaryotes.193,194 The 2’,6’-diamino-substituted 
aminoglycoside antibiotics, for example, were the most potent inhibitors of protein 
synthesis. The 6’-amino-substituted antibiotics were still more effective than the 2’- 
amino-substituted ones, and the unsubstituted antibiotics were the least effective. 
Conversely, other studies using eukaryotic systems found that aminoglycosides with a 
hydroxyl group at the 6’ position were more potent inhibitors.195,196 Anthracycline 
antibiotics such as daunomycin, doxorubicin, and rebeccamycin derivatives which 
contain a 3’-amino group instead of a 3’-hydroxyl group or, for rebeccamycin, a 2’- 
amino group in place of a 2’-hydroxyl group bind more strongly to DNA.197,198 No 
change in activity, however, was seen for cytotoxic and topoisomerase II activity with 
amino-substituted daunomycin and doxorubicin.199 Amino-substituted rebeccamycin, 
likewise, does not affect the activity of topoisomerase I.198
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Other important targets for chemical modification include inhibitors, 
hormones, and substrates. Kati et al., e.g., studied the binding of a- and P-amino acids 
and their analogous hydroxy acids for their ability to inhibit influenza virus 
neuraminidase. They found that 3-chloro-2-hydroxy-5-(/-butyl)-phenylgycine binds 
360 times more strongly than its hydroxy acid analog.200 4-Hydroxy-1-(ethyl - 
isopropyl-carbamoyl)-3-hydroxy-pyrrolidine-3-carboxylic acid has a 2,600-fold 
weaker binding affinity than its P-amino analog.200 Two hydroxyl groups of DANA 
(2,3-didehydro-2-deoxy-A-acetylneuraminic acid), another inhibitor of influenza virus 
neuraminidase, were converted to amino groups. A 100-fold increase in inhibition 
was seen for 4-amino-DANA while a 100-fold decrease was seen for 9-amino-DANA.
7014,9-Diamino-DANA was only a slightly weaker inhibitor compared to DANA.
While 1-hydroxy-1,1-bisphosphonates and 1-amino-1,1-bisphosphonates both 
coordinate magnesium ions, the 1-amino derivatives were found to be better inhibitors 
of Trypanosoma cruzi targeting famesyl pyrophosphate synthase than the 1 -hydroxy-
7 071,1 -bisphosphonates. Conversion of the primary amino group of the hormone
oxytocin to a hydroxyl group resulted in a decrease of binding affinity to its receptor
707neurophysin. However, the hydroxyl-substituted analog of oxytocin still had twice
7 07the activity of the corresponding deamino analog. Glucose-6-phosphate and 
glucosamine-6-phosphate both bind to glucosamine-6-phosphate synthase. The 2’- 
hydroxyl group of glucose-6-phosphate and the 2’-amino group of glucosamine-6- 
phosphate each interact with the same amino acid residues of the enzyme according to 
the crystal structure.204 Both phenyllactyl-tRNAphe and Phe-tRNAPhe bind to the A site
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205of ribosomes in the same manner as determined by X-ray crystallography. The 
ribosome still catalyzes the nulceophilic attack of either the amino or the hydroxyl 
group on the ester carbon of the P-site peptidyl-tRNA via the same mechanism, even 
though the catalytic rate is slower for the phenyllactyl-tRNAPhe.205
Clearly, hydroxyl and amino groups are not universally interchangeable. 
Substitution of an amino group for a hydroxyl group or vice versa can have drastic 
effects on interactions of ligands with biological macromolecules, although some of 
the examples listed above also show that many interactions may remain largely 
unchanged, resulting in only small differences in affinity or activity. Thus, the effect 
of a substitution on a ligand is difficult to predict and multiple parameters may need to 
be studied to determine the full effect of a substitution. Continued progress in 
modeling and structural analysis coupled with binding assays promise to facilitate 
predictions in the future. For certain applications, however, understanding the effects 
of a substitution may be of less importance than knowing the nature and extent of the 
effect itself. Since the substitution of a hydroxyl group for an amino group resulted in 
a complete loss of all detectable binding of anti-AHA antibodies to AAs, the presence 
of AAs such as Phe had no effect on the binding of anti-AHA antibodies to AHAs 
such as PLA. Likewise, the presence of AHAs such as PLA had no effect on the 
binding of anti-AA antibodies to AAs. Therefore, the remarkable stereoselectivity and 
class-specificity of both the anti-AA and anti-AHA antibodies make their use for the 
simultaneous detection of AAs and AHAs appealing.
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The goal of this part of the dissertation was the development and optimization 
of immunoassays for the simultaneous detection of AA and AHA enantiomers using 
anti-AA and anti-AHA antibodies labeled with distinct fluorophores. Fluorophore- 
labeled antibodies were first used in 1941 by Coons et al. for the detection of 
pneumococcus in mammalian tissue using fluorescence microscopy.206,207 Despite 
such early use in histology, fluorescence immunoassays weren’t introduced until 20 
years later when quantitative techniques and more fluorogenic compounds became 
available. Fluorophore-labeled antibodies are now used in, e.g., pathology, 
histology, virology, microbiology, flow cytometry, and immunoassays. While a wide 
range of materials and compounds, including proteins (e.g., green fluorescent protein), 
minerals, lanthanides, and numerous organic compounds, may exhibit fluorescence 
properties, fluorescent organic compounds are most commonly used as labels in 
immunofluorescence. However, chelated lanthanides and fluorescent proteins have 
also been used successfully. Cost, quantum efficiency, hydrophobicity/hydrophilicity, 
stability, and suitability for the desired application should be considered in the 
selection of fluorophores. The DyLight™ fluorophores used in this study are well 
suited for applications such as immunoassays since they are more photostable, 
brighter, and less pH-sensitive than, e.g., fluorescein and rhodamine, which have 
historically been used in many biological and bioanalytical applications.
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Two basic strategies have been employed in immunoassays for the 
detection of multiple analytes.209’210 In one strategy, either an antigen or a capture 
antibody for each analyte is immobilized onto distinct solid supports.210 Color-coded 
or fluorescent beads, microparticles of varying sizes, and even threads have been used
as solid supports.210 Spatial resolution of analytes can also be achieved using discrete
• 211  • • •spots on a single solid phase. Alternatively, antibodies may be labeled with distinct
tags for each analyte to be tested.210 In order to develop fluorescence immunoassays 
for simultaneous detection of multiple analytes, the antibodies used in a given 
multianalyte immunoassay must be sufficiently specific for the desired application. 
Furthermore, fluorophores with sufficiently distinct emission spectra should be used 
for independent detection of multiple differently labeled antibodies within a mixture 
using appropriate filters. The DyLight™ fluorophores used in this study have unique 
emission ranges that can be measured independently. The specificity of the anti-AA 
and anti-AHA antibodies used in this dissertation has already been described in 
Chapter III, section Comparison of Antibody Binding. However, further studies were 
conducted to confirm that no change in antibody binding is seen when combinations of 
antibodies, antigen coatings and analytes are used together in the same sample.
Initial tests were performed by modifying previously established ELISA 
procedures. Noncompetitive ELISAs were conducted using mixtures of antigen 
coatings. In the previously established ELISAs, antigens were coated on the plate 
individually at concentrations of 1 pg/mL. For the modified ELISAs, microtiter plates 
were coated with mixtures of antigens in which each antigen was at a concentration of
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1 [ig/mT, (not shown). Binding curves obtained on mixed coatings did not differ 
significantly from those obtained on individual coatings.
Competitive tests of anti-D-AHA 73 with D-PLA as competitor were carried 
out in the presence of the analogous AA, D-Phe, and anti-D-AA 67.36 antibody. The 
D-Phe was added to the mixture of primary antibodies and competitor so that its 
effective concentration was 10 mM. The anti-D-AA 67.36 was added to the same 
solution. Both antibodies were applied at constant concentrations. The appropriate 
effective concentrations were determined in noncompetitive ELISAs to result in 
absorbance readings of at least 0.8. HRP-labeled goat anti-rabbit F(ab’ )2  secondary 
antibody was used to selectively detect anti-D-AHA 73 bound to the plate.
Comparison of the inhibition curve and relative affinity with previous competitive 
ELISA results of anti-D-AHA 73 with D-PLA showed no significant difference 
(Figure 29). The presence of the other antibody and the D-Phe had no discemable 
effect on the interaction of anti-D-AHA 73 with D-PLA. A second set of competitive 
ELISAs using a mixture of anti-D-AHA 73 and anti-D-AA 67.36 were carried out 
using varying concentrations of D-Phe and a 10 mM effective concentration of D-PLA. 
Bound anti-D-AA 67.36 was selectively detected using HRP-labeled goat anti-mouse 
F(ab’ )2  secondary antibody. Once again, the presence of the other antibody and 
competitor had no significant effect on the interaction of anti-D-AA 67.36 with D-Phe 
(Figure 29).
Thus, ELISAs were successfully used to establish that the binding of anti-D- 
AA 67.36 to D-Phe and of anti-D-AHA 73 to D-PLA were unaffected by the presence
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Figure 29: Competitive ELISAs with a) anti-D-AA 67.36 were carried out using 
varying concentrations of D-Phe in PBS (■ ) and D-Phe in the presence of 10 mM PLA 
and the anti-D-AHA 73 antibody (♦ )  as competitors. For competitive ELISAs with b) 
anti-D-AHA 73, D-PLA in PBS ( • )  and D-PLA in 10 mM D-Phe containing anti-D- 
AA 67.36 (-^) were used as competitors. Error bars indicate standard deviations of 
triplicate determinations. Missing error bars are obscured by symbols.
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of the other antibody and competitor. However, even though the HRP-labeled 
secondary antibodies selectively bind to either mouse or rabbit antibodies, both 
secondary antibodies catalyze the production of the same colored product, making 
simultaneous detection impossible. In the second step of fluorescence immunoassay 
development, therefore, the two primary antibodies were detected simultaneously with 
two different fluorescently labeled secondary antibodies. Noncompetitive binding 
curves for both anti-D-AHA 73 and anti-D-AA 67.36 in fluorescence immunoassays 
did not differ substantially from those obtained in ELISAs (not shown). In the next 
step, in a fluorescence immunoassay, anti-D-AA 67.36 and anti-D-AHA 73 were 
applied in a mixture containing both antibodies at the same concentration used 
previously in competitive ELISAs. A mixture of both D-Phe and D-PLA at 
appropriate concentrations was applied as competitors. Intensity values obtained for 
negative controls were routinely subtracted before calculating percent inhibition 
values. The simultaneous competitive fluorescence immunoassay of anti-D-AA 67.36 
and anti-D-AHA 73 was compared to competitive ELISAs and to competitive 
fluorescence immunoassays of each antibody independently measured with D-Phe and 
D-PLA, respectively (Figure 30). No significant difference in either inhibition curves 
or I C 5 0  values was seen across the three formats for either antibody.
Immunoassays using fluorescently labeled secondary antibodies still limited 
the number of antibody/analyte pairs to a practical maximum of two. This limitation 
was surmounted by fluorescently labeling four primary antibodies with four distinct
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Figure 30: Competitive dual immunoassay performed with anti-D-AHA 73 and anti-D- 
AA 67.36 with both D-Phe and D-PLA as competitors. Two secondary antibodies 
labeled with distinct fluorophores were used to detect anti-D-AA 67.36 and anti-D- 
AHA 73. Measurement at a) 647 nm was used to detect the inhibition of anti-D-AA 
67.36 by D-Phe (■). Measurement at b) 547 nm was used to detect the inhibition of 
anti-D-AHA 73 by D-PLA ( • ) .  Single analyte/antibody fluorescence immunoassays 
gave similar results ( ♦  and-4, respectively). Error bars indicate standard deviations 
of triplicate determinations. Missing error bars are obscured by symbols.
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fluorophores. The four antibodies were selected and labeled as described in 
Chapter II, section Fluorescence Immunoassay. The ratio of fluorophore labels 
conjugated to each of the antibodies were calculated as described in Chapter II, section 
Fluorescence Immunoassay, and are presented in Table 10.
Table 10: Fluorophore-to-antibody ratios of DyLight™ conjugated antibodies
Fluorophore-antibody conjugate number of fluorophores per antibody
anti-D-AHA 8E10 DyLight™ 547 conjugated 6
anti-L-AHA 65 DyLight™ 800 conjugated 11
anti-D-AA polyclonal antibody DyLight™ 647 conjugated 4
anti-L-AA 18.3 DyLight™ 490 conjugated 8
Noncompetitive fluorescence immunoassays were first conducted to confirm 
that the antibodies still selectively bound to only the correct coating after conjugation 
to their respective fluorophores. Microtiter plates were divided into five sections; each 
section was coated with one of five antigens: p-azo-D-PLA-BSA, /?-azo-L-PLA-BSA, 
/7-azo-D-Phe-BSA, p-azo-L-Phe-BSA, or BSA. All four antibodies were tested for 
binding to all five coatings; results are presented in Figure 31 and Figure 32. The 
DyLight™ 647-labeled anti-D-AA polyclonal antibody only bound to the /?-azo-D-
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Figure 31: Noncompetitive fluorescence immunoassay results for a) anti-D-AA 
polyclonal antibody DyLight™ 647 conjugated (stock 0.5 mg/mL) and b) anti-L-AA
18.3 DyLight™ 490 conjugated (stock 1 mg/mL). p-Azo-D-Phe-BSA (■), p-azo-L- 
Phe-BSA (□ ), p-azo-D-PLA-BSA ( • ) ,  p-azo-L-PLA-BSA (O), and BSA were used 
as solid-phase coatings. At each dilution, the values obtained with the BSA coating 
were subtracted from those obtained on the other two coatings.
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Figure 32: Noncompetitive fluorescence immunoassay results for a) anti-D-AHA 8E10 
DyLight™ 547 conjugated (stock 0.5 mg/mL) and b) anti-L-AHA 65 DyLight™ 800 
conjugated (stock 1 mg/mL)./?-Azo-D-PLA-BSA ( • ) ,  />-azo-L-PLA-BSA (O) p-azo- 
D-Phe-BSA (■), /7-azo-L-Phe-BSA (□), and BSA were used as solid-phase coatings. 
At each dilution, the values obtained with the BSA coating were subtracted from those 
obtained on the other two coatings.
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Phe-BSA coating (Figure 31a). The DyLight™ 490 -labeled anti-L-AA 18.3 
bound only to the /?-azo-L-Phe-BSA coating (Figure 31b). The anti-AHA antibodies, 
likewise, bound only to the “correct” coatings. The DyLight™ 547-labeled anti-D- 
AHA 8E10 bound only to the p-azo-D-PLA-BSA (Figure 32a), and the DyLight™ 
800-labeled anti-L-AHA 65 bound only to the p-azo-L-PLA-BSA coating (Figure 
32b). None of the four antibodies showed any significant binding to the BSA coating.
Competitive tests were also used to confirm that the four antibodies retained 
their stereoselective/class-specific binding properties after conjugation. Four so-called 
“single” competitive immunoassays were performed—one test for each of the four 
conjugated primary antibodies with its corresponding competitor having the correct 
structure and configuration (Figure 33 and Figure 34). For example, in the 
fluorescence immunoassay with DyLight™ 547-labeled anti-D-AHA 8E10, D-PLA 
was used as the competitor. Competitive fluorescence immunoassays were then 
repeated using the same four combinations of antibody/competitor in the presence of a 
second competitor, namely the opposite enantiomer at a constant effective 
concentration of 10 mM (Figure 33 and Figure 34). For example, mixtures of L-PLA 
at varying concentrations and D-PLA at a fixed concentration of 10 mM were used as 
competitors with the DyLight™ 800-labeled anti-L-AHA 65 antibody; similarly, a 
mixture of 10 mM L-Phe and varying concentrations of D-Phe were used as 
competitors with the DyLight™ 647-labeled anti-D-AA polyclonal antibody. In the 
final setup, referred to as the “quadruple test,” competitive assays were carried out on 
a mixed coating containing /?-azo-D-PLA-BSA, p-azo-L-PLA-BSA, p-azo-D-Phe-
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Figure 33: A quadruple competitive fluorescence immunoassay was used to 
simultaneously detect D- and L-PLA and D- and L-Phe using four distinctly labeled 
antibodies. Measurement at a) 547 nm was used to detect the inhibition of DyLight™ 
547-labeled anti-D-AHA 8E10 by D-PLA while measurement at b) 774 nm was used 
to detect the inhibition of DyLight™ 800-labeled anti-L-AHA 65 by L-PLA. 
Consistent results were obtained for quadruple ( # ,0 )  and single (V jV ) assays and 
for single assays in which the “opposite” enantiomer was added at a constant 
concentration of 10 mM (►,£>). Closed symbols represent D-PLA and open symbols 
represent L-PLA. Error bars indicate standard deviations of triplicate determinations. 
Missing error bars are obscured by symbols.
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Figure 34: A quadruple competitive fluorescence immunoassay was used to 
simultaneously detect D - and L-Phe and D - and L-PLA using four distinctly labeled 
antibodies. Measurement at a) 647 nm was used to detect the inhibition of DyLight™ 
647-labeled anti-D-AA polyclonal antibody by D-Phe while measurement at b) 494 nm 
was used to detect the inhibition of DyLight™ 490-labeled anti-L-AA 18.3 by L-Phe. 
Consistent results were obtained for quadruple (■ ,□ )  and single ( ♦ , 0 )  assays and 
for single assays in which the “opposite” enantiomer was added at a constant 
concentration of 10 mM (-^,<1). Closed symbols represent D-Phe and open symbols 
represent L-Phe. Error bars indicate standard deviations of triplicate determinations. 
Missing error bars are obscured by symbols.
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BSA, and /?-azo-L-Phe-BSA. All four conjugated antibodies, each at a constant 
concentration, were applied as a mixture, and the four competitors, D- and L-PLA and 
D- and L-Phe, were all applied at appropriate concentrations (Figure 33 and Figure 34). 
For each of the four antibodies, inhibition curves were consistent among all 
fluorescence immunoassays conducted, yielding the same relative affinities for their 
corresponding binding partners. Results were, furthermore, consistent with results 
obtained with antibodies prior to conjugation with fluorophores.
The multianalyte fluorescence immunoassays developed in this study 
demonstrate the simultaneous, stereoselective, class-specific detection of four 
structurally closely related analytes. The exquisite selectivity of the antibodies used in 
these assays provides the basis for simultaneous analyte detection and high-throughput 
assay and array applications. Multianalyte immunoassays can simplify and expedite
the analysis of complex samples and analytes typically tested in groups, thereby
• 2 1 0 2 1 2  • potentially reducing overall costs of testing. ’ Thus, they are ideally suited for
point-of-care use in medicine and for field applications (e.g., environmental
monitoring).213 Despite the exciting potential of multianalyte immunoassays and the
importance of chiral compounds (which has been discussed in Chapter I), the author
has been unable to find any other multianalyte immunoassays for the detection of
chiral analytes. This study for the first time demonstrates the immense potential of
stereoselective antibodies for the sensitive simultaneous detection of structurally
closely related chiral molecules within the same sample.
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Multianalyte assays for achiral applications date back to the late 1980s.
Ekins et al. developed assays based on lanthanide chelate fluorophore labels, which 
are now known as DELFIA, for dissociation-enhanced lanthanide 
fluoroimmunoassay.212 ’2I4’215 Because four different lanthanide chelate labels are 
available, each with distinct emission spectra, DELFIA can be used for the
91 f\ 917simultaneous detection of four analytes. ’ Examples of dual-analyte detection 
assays have been reported using combinations of P-galactosidase with 
phosphodiesterase or alkaline phosphatase or of alkaline phosphatase with horseradish
• • 91 nperoxidase as detection labels. Another simultaneous detection format was the 
dual-label RIA conducted using 125I and 57Co or 125I and 131I tags, which can be 
differentiated by some gamma scintillation counters.210 Dual-labeled simultaneous 
detection has been also performed using metal labels218 and a combination of 
enzyme/radioisotope labels.219
Chiral Immunoaffinity Chromatography
In order to demonstrate that the stereoselective anti-AHA antibodies produced 
in this study are not only suitable for enantiomer detection but also enantiomer 
separation, anti-D-AHA 73 was applied as a chiral selector for the separation of PLA 
enantiomers in chiral immunoaffinity chromatography. Chiral immunoaffinity 
chromatography applies the principles of traditional affinity chromatography (which 
were described in Chapter III, section Production and Characterization of Polyclonal
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Antibodies) to the purification of chiral target molecules using antibodies 
immobilized on a suitable solid phase. For example, in the first application of 
immunoaffinity chromatography to enantiomer separation, polyclonal antibodies 
raised against (i?)-abscisic acid were immobilized on agarose and used to separate 
racemic abscisic acid. After the (5)-enantiomer was eluted, acetone was used to 
disrupt the interaction between the (^)-enantiomer and the immobilized antibody, 
thereby eluting the (i?)-enantiomer.220 Since then, a limited number of both polyclonal 
and monoclonal antibodies have been used for the extraction and separation of 
enantiomers.35
As with other affinity systems, conditions required to elute the bound ligand 
are generally harsh, which may lead to protein denaturation and, therefore, short 
column lifetimes. Weak affinity chromatography (WAC) overcomes these limitations. 
Because many biologically important processes involve weak, reversible interactions, 
WAC is frequently an ideal choice for the characterization of biological events in 
weak affinity systems, including the analysis and isolation of molecules taking part in 
the binding process. Such weak interactions are important in, e.g., virus-cell 
interactions,221 protein-peptide interactions,222 cell adhesion, and cell-cell 
interactions. ' While traditional affinity chromatography involves an on/off 
binding process, WAC exploits weak interactions which are more readily reversible. 
Instead of altering mobile phase conditions to elute an immobilized ligand, isocratic 
conditions can be used in WAC to elute the retained binding partner in a “true 
chromatographic process.”
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Allenmark, in the early 1980s, for the first time showed the application of 
weak affinity systems for the separation of enantiomers under isocratic conditions 
using BSA as chiral selector.226 Later, Zopf and Ohlson used monoclonal antibodies 
with weak affinities to an oligosaccharide in, what they termed, WAC. 227 Several 
chiral selectors exploit weak interactions for the separation of enantiomers; this 
includes cyclodextrins, 228 brush-type CSPs, 229 protein CSPs, 230,231 and even some 
MIPs.232,233
Hofstetter et al. were the first to demonstrate WAC using antibody-based 
CSPs.63 They used both POROS, a polymeric high-flow-through-type support, 63,64 
and silica66,69,70 as solid supports for separation of AA enantiomers. AAs of the 
correct configuration bound reversibly to the antibody and were retained on the CSP, 
while analytes that do not interact with the antibody eluted with the void volume. 
Because the bound enantiomer eluted using mild isocratic conditions, the columns 
could be used for hundreds or even thousands of separations. 64,66 Such stable 
columns, which were even used typically at room temperature, are practical for routine 
separations of enantiomers. Various chromatographic parameters such as temperature 
and flow rate were shown to affect the binding strength between analyte and 
immobilized antibody. 64 Additionally, Hofstetter et al. were able to show that 
miniaturization can reduce consumption of both stationary phase material and 
antibody by using microbore columns. 66,69 The use of such miniaturized systems also 
allowed interfacing columns with mass spectrometers for detection. 66 Recently,
Gtibitz et al. studied the separation of enantiomers of the thyroid hormone T3 .234
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Separations were achieved by using stereoselective antibody against L-T3 as chiral 
selector in micro-HPLC. The enantiomers were separated under mild continuous 
isocratic elution conditions using 10 mM phosphate buffer, pH 7.4. The unretained D- 
enantiomer eluted with the void volume, whereas the L-enantiomer was retained by 
the antibody phase and eluted later.
In this study, the anti-D-AHA 73 was immobilized on silica, which had been 
packed in a 200 mm x 0.75 mm i.d. PEEK column as described in Chapter II, section 
Chiral Immunoaffinity Chromatography. A nonracemic mixture of PLA was 
separated under isocratic conditions at room temperature using PBS as mobile phase. 
The two enantiomers of PLA were separated with a resolution of 1.44 (Figure 35). 
Considerable peak tailing was observed on this column for the more retained 
enantiomer. Such peak tailing, typically observed even at low concentrations of 
analyte, is common on columns with protein-based stationary phases and is best 
explained by slow dissociation kinetics.
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Figure 35: The enantiomers of PLA were separated using anti-D-AHA 73 as a chiral 
selector in a 0.75 x 200 mm microbore column packed with silica. Separations were 
achieved under isocratic conditions using PBS as mobile phase. Analytes were 
detected by measuring UV absorbance at 205 nm.
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SUMMARY
In this research, remarkably specific antibodies were produced that 
stereoselectively bind to the enantiomers of AHAs. In order to produce stereoselective 
antibodies to free AHAs, conjugates of/?-amino-D- and -l-PLA and KLH were 
synthesized and used for the immunization of rabbits and mice. While polyclonal 
antibodies were obtained from the interstitial fluid or sera of rabbits, monoclonal 
antibodies were produced using hybridoma technology.
The binding characteristics and stereoselectivity of these antibodies were tested 
in noncompetitive and competitive ELISAs. The animals inoculated with the L- 
enantiomer of the hapten produced antibodies that only bind to the L-enantiomers of 
AHAs. Conversely, the animals inoculated with the D-enantiomer produced 
antibodies that only bind to the D-enantiomers of AHAs. The affinity of these 
antibodies to a variety of different AHAs was tested to evaluate the influence of the 
side chain to the overall strength of interaction. These antibodies proved effective for 
the sensitive, stereoselective discrimination of AHAs ranging from aromatic AHAs to 
aliphatic AHAs such as lactic acid. However, AHAs resembling the hapten were 
found to bind more strongly to the antibodies than do AHAs with aliphatic side chains.
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These antibodies have been tested not only for their ability to 
stereoselectively bind various AHAs but also for their ability to distinguish between 
different classes of compounds. AHAs and AAs are similar classes of compounds that 
differ only in one functional group bound to the chiral carbon. Further ELISAs were 
performed to test the binding of an AA to the anti-AHA antibodies. Conversely, 
previously produced anti-AA antibodies were tested for their ability to bind to AHAs. 
Surprisingly, the anti-AHA antibodies do not bind at all to AAs nor do the anti-AA 
antibodies bind to AHAs. Neither did the anti-AHA antibodies bind to the structurally 
related compounds phenylpropionic acid (in which the hydroxyl group of PLA is 
substituted by a hydrogen atom) and PLA methyl ester (in which the carboxyl group 
of PLA is exchanged to a methyl ester derivative). The hydrogen/hydroxyl/carboxyl 
triad about the stereogenic center of AHAs is clearly essential for the interaction with 
the anti-AHA antibodies studied in this dissertation. A change in either hydroxyl or 
carboxyl functional groups resulted in a loss of all detectable interaction.
The exquisite stereoselectivity and class-specificity of the produced anti-AHA 
antibodies make them particularly useful for bioanalytical techniques. Enantiomer 
separation of PLA demonstrated the utility of the anti-AHA antibodies for chiral 
chromatography. The applicability of the antibodies as chiral selectors was further 
demonstrated in a fluorescence immunoassay that allowed the simultaneous detection of 
D-Phe, L-Phe, D-PLA, and L-PLA. Four antibodies, each of which binds only to 
analytes having the correct target structure and configuration, were conjugated to a
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unique fluorophore, which enabled independent detection and quantitative 
measurement of the four analytes contained within the same sample.
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APPENDIX
BUFFER AND CELL CULTURE MEDIA PREPARATION
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Phosphate-Buffered Saline
158
A stock solution of 20x PBS is prepared by dissolving 48 g of sodium 
phosphate dibasic, 8  g of potassium phosphate monobasic, 8  g of potassium chloride, 
and 320 g of sodium chloride in two liters of water. PBS is made by diluting the 
stock solution of 20x PBS by a factor of 20 with water.
Carbonate Buffer
Sodium bicarbonate (2.1 g) and sodium carbonate (2.65 g) are each dissolved 
in 500 mL of water to make 50 mM sodium bicarbonate and 50 mM sodium 
carbonate solutions, respectively. Carbonate buffer is prepared by adding 50 mM 
sodium carbonate to 500 mL of 50 mM sodium bicarbonate until the pH of the buffer 
is 9.6.
Citrate-Phosphate Buffer
Stock solutions of 100 mM citric acid and 200 mM sodium phosphate dibasic 
are made by dissolving 19.2 g of citric acid and 3.56 g of sodium phosphate dibasic, 
respectively, in 100 mL of water each. Stock solutions are stored at 4°C until needed. 
Citrate-phosphate buffer is made by mixing 4.8 mL of 100 mM citric acid, 5.2 mL of 
200 mM sodium phosphate dibasic, and 10 mL of water.
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Tris/HCl Buffer
One hundred mM Tris buffer is made by adding 6.05 g of Trizma base to 500 
ml, of water and adjusting the pH to 7.0 with HC1.
PBS/Tween 20
PBS/Tween 20 buffer is made by adding 1 mL of Tween 20 to two liters of
PBS.
OPD ELISA Substrate
Citric acid (0.1 M, 4.8 mL) and sodium phosphate dibasic (0.2 M, 5.2 mL) are 
combined with 10 mL of water, then 8  mg of 1,2-phenylenediamine are added. After 
mixing thoroughly, 13pL of 30% hydrogen peroxide are added.
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Cell Culture Medium
160
Cell culture medium is prepared by dissolving 10.4 g of RPMI-1640 medium 
powder in 750 mL of ultrapure water. The pH is transiently (for approximately 20 
minutes) lowered to 4.0 with 1 N hydrochloric acid to aid in dissolving the medium. 
After readjusting the pH to 7.2 with 1 N sodium hydroxide, 2.5 g of glucose, 1.5 g of 
sodium bicarbonate, and 2.4 g of HEPES are added to the medium. More ultrapure 
water is added to bring the volume to 840 mL. Under sterile conditions, 10 mL of 
sodium pyruvate is added. The medium is filtered, stored at 4°C, and warmed up to 
37°C before feedings.
The medium for myeloma cells is supplemented with horse serum and 
antibiotic-antimycotic. Before feeding, 1 mL of antibiotic-antimycotic and 15 mL of 
horse serum are added to 86 mL of RPMI medium. The medium for hybridoma cells 
is supplemented with HAT, horse serum, and antibiotic-antimycotic. One vial of 50x 
HAT media supplement is dissolved in 10 mL of prepared medium. Before feeding,
2 mL of HAT, 1 mL of antibiotic-antimycotic, and 15 mL of horse serum are added to 
84 mL of RPMI medium.
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